U.S. Home-Based Neurology Devices Market: 12.18% CAGR

Market Outlook

By 2035, the U.S. Home-Based Neurology Devices Market is expected to reach approximately USD 8.46 billion, expanding at a CAGR of 12.18% during the forecast period 2026-2035. The market was valued at USD 2.68 billion in 2025, with historical analysis covering 2021-2024. Values in this report are expressed in USD billions. The market size is an analyst estimate developed through triangulation of device shipments, installed-base replacement, average selling prices, payer-supported utilization, company disclosures, provider adoption patterns, and the recurring software or consumable revenue attached to home-use neurological platforms.

The market includes prescription, clinician-supervised, FDA-regulated, and medically oriented devices used primarily in the patient residence for neurological diagnosis, monitoring, therapy, rehabilitation, safety, or longitudinal disease management. The scope covers ambulatory electroencephalography, wearable seizure detection, tremor and dyskinesia monitoring, connected gait and balance assessment, noninvasive migraine neuromodulation, vagus nerve stimulation platforms, functional electrical stimulation, home neurorehabilitation systems, caregiver alert devices, and software-linked sensors that convert home data into clinically actionable neurological information. Hospital-only capital equipment, general consumer wellness wearables without a neurological use case, and non-device home care services are excluded unless they are directly bundled with a medical device platform.

The U.S. market is moving from episodic neurological evaluation toward continuous, home-centered observation. This change is economically important because many neurological disorders are intermittent, progressive, or highly variable between office visits. Epileptic events may not occur during a short in-clinic EEG. Parkinsonian symptoms fluctuate with medication timing. Migraine frequency and treatment response depend on longitudinal diaries. Stroke recovery changes week by week. Cognitive decline can be difficult to identify through a single annual assessment. Home-based devices create a higher-resolution view of patient status and help neurologists determine whether a symptom change represents true deterioration, medication response, adherence failure, or environmental variation.

Historical market value increased from approximately USD 1.66 billion in 2021 to USD 2.34 billion in 2024. Expansion was supported by the normalization of ambulatory diagnostics after the pandemic, stronger acceptance of remote patient monitoring, growth in prescription migraine devices, wider use of wearable motion sensors, and increased payer and provider interest in reducing avoidable emergency visits. The market reached USD 2.68 billion in 2025 as neurologists, integrated delivery networks, specialty pharmacies, home healthcare organizations, and rehabilitation providers accelerated deployment of connected devices that can be used without repeated travel to tertiary centers.

The forecast is intentionally aggressive but defensible. Demand is being pulled by a rapidly aging population, high prevalence of epilepsy, migraine, stroke disability, Parkinson disease, multiple sclerosis, dementia, and neuropathic conditions. Supply-side growth is being driven by smaller sensors, improved battery performance, edge computing, smartphone connectivity, AI-assisted event detection, cloud review, remote programming, and lower-friction patient onboarding. The strongest growth will occur where a device has a clear clinical decision pathway, a reimbursement route, measurable caregiver value, and evidence that it can reduce diagnostic delay or downstream utilization.

Introduction

According to the U.S. Home-Based Neurology Devices Market Report, the industry sits at the intersection of neurology, medical devices, digital health, home care, rehabilitation, and specialty pharmacy. It is not a uniform category. Revenue comes from diagnostic hardware, wearable sensors, disposable electrodes, prescription neuromodulation systems, home rehabilitation equipment, cloud platforms, patient support programs, device rentals, and recurring monitoring services. This mixed revenue architecture gives the market a combination of durable equipment economics and subscription-like recurring value.

The clinical need is substantial. Approximately 2.9 million U.S. adults reported active epilepsy in 2021-2022. An estimated 7.2 million Americans age 65 and older were living with Alzheimer disease in 2025. Nearly 90,000 people are diagnosed with Parkinson disease in the United States each year. Stroke remains a leading source of long-term disability, and national data indicate that millions of adults have a history of stroke. These populations do not require the same device, but they share a common care problem: symptoms and functional capacity change at home, while specialist decisions are often made from infrequent clinic encounters.

Demographics reinforce the opportunity. The U.S. population age 65 and older reached approximately 61.2 million in 2024, rising faster than the overall population. Older adults account for a disproportionate share of Parkinson disease, dementia, stroke, gait instability, falls, neuropathy, and polypharmacy-related neurological complications. At the same time, family caregivers provide a large portion of daily neurological support. Devices that automate observation, trigger alerts, simplify treatment, or document functional change can reduce caregiver uncertainty and create earlier intervention opportunities.

The market is closely tied to specialist access. Neurologists are concentrated in metropolitan and academic markets, while many rural and lower-density communities face longer travel times and delayed appointments. Home EEG, tele-neurology-linked monitoring, connected rehabilitation, and wearable movement analytics can extend specialist capacity without pretending to replace specialist judgment. The commercial value is highest when technology filters large volumes of home data and presents clinicians with interpretable trends rather than raw, unprioritized signals.

Reimbursement is expanding but remains uneven. Medicare broadly supports remote physiologic monitoring for medically necessary collection of physiologic data, while billing rules require device supply, data capture, and clinical management components to be documented correctly. Neurology devices may also be reimbursed through diagnostic testing, durable medical equipment, outpatient therapy, specialty pharmacy, commercial medical policy, or cash-pay channels. This fragmented coverage environment favors companies that build reimbursement support, patient eligibility verification, clinician training, and documentation workflows into the commercial model.

From 2026 to 2035, the central strategic transition will be from standalone devices to care pathways. A seizure wearable without alert escalation, a tremor sensor without medication review, or a rehabilitation device without therapist feedback has limited enterprise value. Platforms that connect the patient, caregiver, neurologist, therapist, home health team, and payer will capture a larger share of spending because they address the full workflow around neurological deterioration and recovery.

Key Market Drivers: What’s Fueling the U.S. Home-Based Neurology Devices Market Boom?

The first major driver is the scale and chronicity of neurological disease. Epilepsy, migraine, Parkinson disease, dementia, stroke sequelae, multiple sclerosis, essential tremor, neuropathic pain, and neuromuscular disorders often require years of observation and treatment adjustment. The economic model therefore differs from one-time diagnostic markets. A home-based platform can generate recurring demand through sensors, disposables, software, replacement hardware, clinical review, and patient support over a long disease course.

A second driver is the inability of periodic office visits to capture symptom variability. Parkinsonian tremor, bradykinesia, dyskinesia, gait freezing, seizures, sleep disruption, migraine attacks, fatigue, and post-stroke performance are influenced by time of day, medication timing, stress, environment, and adherence. Objective home data can identify patterns that patients and caregivers may not recall accurately. This is particularly valuable in neurology, where treatment decisions frequently depend on event frequency, functional decline, or response between visits.

A third driver is the migration of diagnostic and therapeutic activity away from the hospital. Ambulatory EEG can capture multi-day brain activity in a natural environment. Prescription neuromodulation can allow migraine treatment without an infusion center or emergency department. Home rehabilitation devices can extend therapy beyond a limited number of in-person sessions. This migration improves patient convenience, but the more important market effect is improved asset utilization for providers and a potential reduction in high-cost facility encounters.

A fourth driver is the caregiver economy. Dementia, epilepsy, Parkinson disease, stroke disability, and neuromuscular disease can create continuous supervision needs. Caregivers want reliable alerts, simple device setup, clear escalation protocols, and evidence that a device is clinically meaningful. Manufacturers that treat the caregiver as a core user – not merely an accessory to the patient – can improve retention, adherence, and willingness to pay. Caregiver-facing design is especially important for pediatric epilepsy, advanced movement disorders, and cognitive impairment.

A fifth driver is the growth of remote monitoring reimbursement and value-based care. Medicare and commercial payers are increasingly willing to reimburse structured remote monitoring when it is medically necessary and connected to clinical management. Neurology practices are also under pressure to manage larger panels with limited specialist supply. Devices that create billable, protocolized, and time-efficient workflows can improve practice economics. However, reimbursement alone will not create sustainable demand; devices must reduce manual review burden and support clear clinical action.

A sixth driver is improvement in sensor and connectivity performance. Modern devices can combine accelerometry, gyroscopes, electrodermal activity, surface electromyography, EEG, temperature, heart rate, sleep, and patient-reported information. Smartphones provide a ready connectivity layer, while cloud systems enable remote review and algorithm updates. The resulting data density is making home neurology more clinically credible, although validation, false alarms, battery life, and data completeness remain procurement concerns.

A seventh driver is hospital and integrated delivery network procurement strategy. Neurology service lines are increasingly evaluated on access, emergency utilization, readmissions, therapy capacity, and specialist productivity. Health systems may adopt home devices when they can shorten diagnostic queues, discharge patients with a safer follow-up plan, expand a stroke or epilepsy program, or support rural outreach. Enterprise buyers assess total pathway cost, interoperability, cybersecurity, patient onboarding burden, and vendor service reliability rather than device price alone.

Innovation in Focus: How Manufacturers Are Raising the Bar?

Innovation in the U.S. home-based neurology devices market is moving toward multimodal sensing, clinically interpretable analytics, and patient-specific baselines. Neurological symptoms are rarely represented by one signal. A Parkinson platform may need motion, medication timing, speech, sleep, and patient-reported outcomes. A seizure platform may combine movement, electrodermal activity, heart rate, or EEG. The strategic objective is to distinguish clinically meaningful change from ordinary variation in daily activity.

Ambulatory EEG is becoming lighter, less intrusive, and easier to deploy. Traditional systems required wired recorders, extensive electrode preparation, and frequent technical support. Newer architectures use compact wireless amplifiers, reduced montages, wearable patches, in-ear sensing, and cloud upload. The commercial opportunity is not limited to hardware. Providers need logistics, patient education, electrode support, quality control, interpretation workflow, and fast reporting. Companies that integrate these services can turn ambulatory EEG into a scalable national diagnostic pathway.

Seizure detection is advancing from motion-only alerts to multimodal systems. FDA-cleared wearable systems can support adjunctive monitoring in the home, while newer platforms use improved sensors and algorithms to reduce false alarms. The market is likely to expand beyond detection toward risk stratification, nocturnal monitoring, caregiver escalation, medication adherence, and documentation for specialist review. Manufacturers must be careful not to overstate capability because home seizure devices are adjuncts and do not replace direct observation or emergency planning.

Prescription migraine neuromodulation is another high-growth innovation area. Remote electrical neuromodulation, external trigeminal stimulation, and noninvasive vagus nerve stimulation offer drug-free or drug-sparing options for acute and preventive treatment. These products are particularly relevant for patients who cannot tolerate medications, have contraindications, or want to reduce rescue-drug use. Commercial success depends on prescription access, specialty pharmacy fulfillment, patient education, repeat use, and evidence that the device fits real-world migraine behavior.

Movement-disorder monitoring is shifting from short clinic examinations to continuous or repeated home measurement. Wearable tremor and dyskinesia systems can quantify movement fluctuations, gait, bradykinesia, and treatment response. The next generation will connect these measurements to medication optimization, deep brain stimulation follow-up, fall risk, and speech or cognitive change. Platforms that integrate with common consumer devices may scale faster, but medical-grade validation and data governance remain important differentiators.

Home neurorehabilitation is becoming more connected and task-specific. Functional electrical stimulation, powered orthoses, hand-training systems, sensorized exercise equipment, virtual reality, and game-based therapy can extend repetitions beyond the clinic. This matters because neurological recovery is strongly influenced by intensity and consistency. The winning systems will not simply digitize exercises; they will measure quality of movement, adapt difficulty, transmit progress to therapists, and identify when in-person reassessment is required.

AI is increasingly used for event detection, signal quality control, trend analysis, patient prioritization, and clinician workflow. The most credible applications are narrow and clinically bounded. Algorithms can flag a likely seizure, detect a change in gait, identify poor EEG signal, or prioritize patients with worsening home performance. Buyers remain cautious about black-box decision making. Manufacturers will need transparent performance metrics, subgroup validation, cybersecurity controls, and human oversight to gain broad health-system adoption.

Manufacturers are also raising the bar through evidence generation. Enterprise customers want prospective studies, real-world performance, usability data, health economic analysis, and proof that patients can use the device correctly outside a controlled setting. Evidence on false alarms, adherence, abandonment, caregiver burden, and workflow time is becoming as important as technical accuracy. A product that performs well in a laboratory but fails in home logistics will struggle to sustain reimbursement and renewals.

Segmentation Insights

The U.S. Home-Based Neurology Devices Market is segmented on the basis of product category, application, end user, technology type, and region. The segmentation reflects how buyers evaluate the market: what the device does, which neurological condition it addresses, who operates the care pathway, which sensing or therapeutic technology creates value, and where adoption is concentrated.

By Product Category

Home Neurodiagnostic and Ambulatory Monitoring Devices

Home neurodiagnostic and ambulatory monitoring devices represent the largest product category in 2025. The segment includes ambulatory EEG recorders, wireless EEG sensors, portable neurophysiology systems, home sleep-neurology testing components, event recorders, and associated electrodes, amplifiers, carrying systems, and data-transfer software. Demand is driven by diagnostic uncertainty, limited epilepsy monitoring unit capacity, and the need to capture events over several days. Revenue is supported by both capital or rental equipment and recurring disposable use. The segment will remain central because objective brain-signal acquisition has a direct path to diagnosis and treatment decisions.

Wearable Seizure, Tremor, Gait and Movement Monitoring Devices

Wearable neurological monitoring devices include wrist-worn seizure alerts, accelerometer and gyroscope systems, tremor sensors, dyskinesia monitors, gait and balance trackers, fall-risk devices, and connected motion platforms. This category benefits from lower hardware costs and smartphone connectivity, but it faces significant validation requirements. Growth will be strongest in systems that establish a personal baseline and detect clinically relevant deviation rather than comparing every patient with a generic population norm. Parkinson disease, epilepsy, essential tremor, multiple sclerosis, and post-stroke mobility are the principal demand areas.

Noninvasive Neuromodulation and Therapeutic Devices

Noninvasive neuromodulation is one of the fastest-growing product categories. It includes remote electrical neuromodulation for migraine, external trigeminal nerve stimulation, noninvasive vagus nerve stimulation, prescription electrical stimulation for neuropathic symptoms, and selected home-use brain stimulation platforms. These devices compete with medication, not only with other hardware. Their value proposition includes rapid use at home, lower systemic side effects, reduced dependence on rescue medication, and potential preventive benefit. Repeat consumables, subscription models, and specialty pharmacy distribution can create attractive recurring revenue.

Home Neurorehabilitation, Functional Stimulation and Mobility Devices

This segment includes functional electrical stimulation systems for foot drop or upper-limb recovery, powered orthoses, hand and arm trainers, sensorized balance equipment, connected rehabilitation kits, home robotics, and virtual-reality-enabled therapy devices. Stroke is the largest use case, followed by multiple sclerosis, spinal cord injury, traumatic brain injury, cerebral palsy, and neurodegenerative disease. Adoption depends on therapist involvement, patient motivation, ease of donning, and the ability to demonstrate functional progress. Products that can support hybrid therapy models are expected to outperform equipment sold without clinical integration.

Connected Safety, Cognitive and Caregiver Support Devices

Connected safety and caregiver support devices include medically oriented fall detection, wandering alerts, medication-linked neurological monitoring, cognitive assessment hardware, speech or communication aids, and sensors used to identify changes in routine or function. The category is smaller and more fragmented because many products sit near the boundary between medical device and consumer technology. Growth will be strongest where the system is tied to a care plan, clinician dashboard, or reimbursed service rather than marketed only as general senior technology.

By Application

Epilepsy and Seizure Disorders

Epilepsy and seizure management is the largest application segment. Approximately 2.9 million U.S. adults reported active epilepsy in 2021-2022, and pediatric epilepsy adds another clinically important population. Home-based devices address three core needs: capturing diagnostic EEG outside the hospital, detecting convulsive events, and alerting caregivers. The market is particularly attractive for nocturnal monitoring, drug-resistant epilepsy, pediatric households, and patients with infrequent events that are difficult to record during routine testing. Long-term growth will depend on improved sensitivity, lower false-alarm rates, better battery reliability, and integration with epilepsy center workflows.

Migraine and Headache Disorders

Migraine is the fastest-scaling therapeutic application because the patient pool is large, treatment occurs at home, and patients frequently seek non-drug options. National survey data show that millions of U.S. adults experience disabling headache or migraine symptoms. Prescription neuromodulation devices can be positioned for acute treatment, prevention, or both. The segment has a consumer-like adoption dynamic but remains clinically regulated. Successful companies use digital onboarding, specialty pharmacy support, refill or replacement programs, and outcomes tracking to maintain engagement after the initial prescription.

Parkinson Disease, Essential Tremor and Movement Disorders

Movement disorders represent a high-value application because symptoms fluctuate and medication adjustment is complex. Nearly 90,000 people are diagnosed with Parkinson disease in the United States each year. Home sensors can quantify tremor, bradykinesia, dyskinesia, gait, falls, and daily activity. Data can support medication timing, advanced therapy evaluation, and post-procedure follow-up. The application also includes essential tremor, Huntington disease, dystonia, and selected ataxias. Adoption will expand as neurologists gain confidence that wearable metrics correlate with meaningful functional outcomes.

Stroke, Traumatic Brain Injury and Neurorehabilitation

Stroke and acquired brain injury create sustained demand for home rehabilitation devices. Millions of U.S. adults live with a history of stroke, and mobility is reduced in a substantial share of older survivors. The economic opportunity is driven by the gap between the intensity of rehabilitation needed and the number of reimbursed in-person sessions available. Functional electrical stimulation, hand rehabilitation, gait training, balance systems, and connected exercise platforms can extend therapeutic repetitions. Buyers will prioritize devices that demonstrate transfer from measured exercise performance to real-world activities of daily living.

Dementia, Multiple Sclerosis and Other Chronic Neurological Conditions

Dementia, multiple sclerosis, neuromuscular disease, neuropathy, and chronic neurological pain form a diverse application segment. In 2025, approximately 7.2 million Americans age 65 and older were living with Alzheimer disease, while population-based research has estimated that close to one million people in the United States live with multiple sclerosis. Home devices in these conditions focus on safety, cognition, mobility, fatigue, falls, treatment adherence, and early identification of deterioration. The market is less standardized than epilepsy or migraine, but it offers substantial long-term potential because caregiver burden and specialist access constraints are severe.

By End User

Neurology Practices and Specialty Centers

Neurology practices, epilepsy centers, headache clinics, movement-disorder programs, and academic medical centers are the clinical gatekeepers for the market. They prescribe devices, interpret home data, establish protocols, and determine whether the information changes treatment. Academic centers often act as early adopters and evidence generators, while large private neurology groups can scale deployment rapidly when workflow and reimbursement are clear. Vendors must support ordering, patient enrollment, data review, billing documentation, and escalation without increasing administrative burden.

Hospitals, Integrated Delivery Networks and Home-Centered Care Programs

Hospitals and integrated delivery networks use home neurology devices to extend service lines beyond the campus. Epilepsy programs can use ambulatory EEG to reduce diagnostic backlogs. Stroke programs can discharge patients with connected rehabilitation or fall-risk support. Movement-disorder centers can monitor patients who live far from the tertiary center. Procurement decisions are typically enterprise-level and include cybersecurity, electronic health record integration, contracting, clinical governance, and device fleet management. Health systems are willing to pay for scale when the technology improves access or reduces avoidable facility utilization.

Home Healthcare and Remote Patient Monitoring Providers

Home healthcare organizations and remote monitoring providers are emerging as important operational users. They can support setup, patient education, adherence, caregiver communication, and escalation to the neurologist. This channel is especially relevant for older adults, patients with mobility limitations, and rural populations. The commercial challenge is that many neurological signals are more complex than blood pressure or weight. Providers need specialized protocols and trained clinical staff to avoid generating alarms that cannot be interpreted or acted upon.

Rehabilitation Providers and Therapy Networks

Inpatient rehabilitation facilities, outpatient therapy groups, home health therapists, and hybrid rehabilitation networks drive demand for functional stimulation and connected neurorehabilitation devices. Their purchasing priorities include evidence of functional improvement, therapist efficiency, patient adherence, remote progress visibility, and compatibility with reimbursement rules. Devices that allow one therapist to manage a larger home caseload without compromising safety can create a compelling economic case. The segment is sensitive to coverage limits and therefore benefits from rental, subscription, or bundled-care models.

Patients, Caregivers and Direct Fulfillment Channels

Patients and caregivers are increasingly influential even when a prescription is required. They compare usability, portability, comfort, battery life, app design, replacement cost, privacy, and customer support. Specialty pharmacies, device distributors, manufacturer-direct programs, and selected online channels facilitate fulfillment. Direct engagement can accelerate adoption, but companies must maintain clinical discipline and avoid consumer-marketing claims that exceed the cleared indication. Patient abandonment after the first month is a major commercial risk, making onboarding and support essential.

By Technology Type

Wearable Biosensors and Motion Analytics

Wearable biosensors are the largest technology layer by unit volume. Accelerometers, gyroscopes, electrodermal activity sensors, temperature sensors, optical heart-rate sensors, and surface electromyography can be combined to characterize movement, autonomic change, sleep, or event patterns. These technologies benefit from miniaturization and consumer familiarity. Their limitation is that a signal may be affected by environment, device placement, mobility aids, or unrelated illness. Clinical-grade analytics must therefore focus on validated use cases and within-patient trends.

Ambulatory EEG and Neurophysiology

Ambulatory EEG and neurophysiology systems dominate high-acuity diagnostic value. They include full-montage recorders, reduced-montage wearables, wireless sensors, amplifiers, electrode systems, cloud upload, and review software. The technology requires strong signal quality, artifact management, secure data transfer, and trained interpretation. It is likely to remain one of the most defensible market segments because it produces clinically recognized physiological data and supports a defined diagnostic service.

Electrical and Peripheral Nerve Stimulation

Electrical stimulation technologies include remote electrical neuromodulation, trigeminal stimulation, vagus nerve stimulation, transcutaneous stimulation, functional electrical stimulation, and selected noninvasive brain stimulation approaches. Growth is driven by migraine, rehabilitation, neuropathic symptoms, and movement-related impairment. Device differentiation depends on waveform, electrode placement, treatment protocol, comfort, safety controls, and evidence. The technology can scale efficiently at home, but reimbursement varies considerably by indication and product.

Connected Robotics, Orthotics and Virtual Rehabilitation

Connected robotics and rehabilitation technologies combine mechanical assistance, sensorized movement, adaptive software, and therapist dashboards. Products range from powered hand devices and foot-drop systems to gait trainers and home exercise platforms. The hardware can command a higher selling price, while software creates recurring revenue and remote clinical visibility. Adoption is strongest when the product is easy to set up, supports measurable goals, and can be used safely without continuous professional supervision.

AI, Cloud Platforms and Interoperability

AI and cloud platforms form the integration layer across the market. They support signal quality checks, event detection, data compression, trend visualization, patient prioritization, and electronic health record exchange. Although software represents a smaller standalone revenue pool, it materially influences device selection because it determines clinician workload. Interoperability with smartphones, telehealth platforms, hospital identity systems, and clinical documentation will become a procurement requirement rather than an optional feature.

Regional Insights: Where the Market is Growing Fastest

The U.S. Home-Based Neurology Devices Market is geographically segmented into the South, Northeast, West, and Midwest. Regional performance differs according to population scale, age distribution, neurological disease burden, tertiary neurology capacity, broadband access, home health penetration, integrated delivery network concentration, payer mix, and willingness to adopt remote specialty care. The South represented the largest regional market in 2025, while the West is projected to record the fastest growth through 2035. The Northeast remains the highest-acuity and most research-intensive market, and the Midwest provides a stable base with strong medtech capabilities and high need for rural outreach.

South

The South accounted for an estimated USD 0.95 billion in 2025, making it the largest regional market. The region includes Texas, Florida, Georgia, North Carolina, Virginia, Tennessee, South Carolina, Alabama, Mississippi, Louisiana, Arkansas, Kentucky, Oklahoma, West Virginia, Maryland, Delaware, and the District of Columbia under the report’s commercial geography. Growth is supported by rapid population expansion, a large older-adult base, high stroke and chronic disease burden, extensive Medicare enrollment, and significant rural access gaps.

Texas and Florida are the two most important state markets. Texas combines large urban neurology hubs in Houston, Dallas-Fort Worth, Austin, and San Antonio with vast rural areas that require remote diagnostics and monitoring. Its major academic centers, pediatric epilepsy programs, rehabilitation hospitals, and integrated delivery networks create demand across ambulatory EEG, seizure monitoring, migraine devices, movement analytics, and neurorehabilitation. Florida has one of the country’s largest older populations, supporting strong demand for Parkinson monitoring, dementia safety systems, stroke rehabilitation, gait assessment, and caregiver-facing technologies. Florida also has a large home health and Medicare Advantage ecosystem that can accelerate deployment when vendors demonstrate reduced utilization.

North Carolina, Georgia, Virginia, Tennessee, and Maryland are high-opportunity states because they combine research institutions, fast-growing metropolitan populations, and regional referral networks. North Carolina and Maryland are influential for clinical research and digital health adoption. Georgia and Tennessee have large catchment areas where ambulatory diagnostic services can reduce travel to specialty centers. Virginia benefits from a mix of academic care, military and veteran populations, and rural communities. These states are attractive launch markets for enterprise partnerships because a small number of health systems can influence a large share of specialty care.

Alabama, Mississippi, Louisiana, Arkansas, Kentucky, Oklahoma, and West Virginia present a different opportunity profile. Stroke prevalence and disability burden are elevated in many nonmetropolitan areas, while specialist density and transportation access are constrained. The most commercially relevant devices are those that are simple to deploy, work with limited connectivity, and include human support. Vendors should expect slower procurement and greater reimbursement sensitivity, but they can create strong value by preventing repeated travel, identifying deterioration earlier, and enabling home rehabilitation.

The South is forecast to reach approximately USD 3.02 billion by 2035. It will remain the largest market because of population scale and disease burden. Growth will be driven by integrated delivery network adoption, Medicare Advantage care management, home health partnerships, ambulatory EEG expansion, migraine neuromodulation, and connected stroke rehabilitation. Companies that can serve both high-volume urban systems and lower-resource rural markets will have the strongest regional position.

West

The West represented an estimated USD 0.60 billion in 2025 and is expected to be the fastest-growing region, reaching approximately USD 2.16 billion by 2035. The region includes California, Washington, Arizona, Colorado, Oregon, Nevada, Utah, New Mexico, Idaho, Montana, Wyoming, Alaska, and Hawaii. Its growth advantage is based on digital-health adoption, venture-backed innovation, strong technology infrastructure, progressive integrated delivery networks, and a large population comfortable with connected care.

California is the dominant state market in the West. It has a large and diverse patient population, major academic neurology centers, advanced epilepsy and movement-disorder programs, and a dense ecosystem of software, sensor, AI, and medtech companies. California providers are likely to evaluate new home EEG architectures, wearable neurological endpoints, migraine devices, and virtual rehabilitation earlier than many other markets. The state also creates a demanding compliance environment, making privacy, cybersecurity, multilingual onboarding, and accessibility critical to commercialization.

Arizona, Nevada, Colorado, and Utah are high-growth states. Arizona and Nevada benefit from rapid population growth and aging migration, which increase demand for stroke recovery, Parkinson care, fall-risk monitoring, and dementia support. Colorado and Utah have strong integrated health systems, research-oriented providers, and technology-friendly populations. Washington and Oregon show favorable adoption of telehealth-linked specialty care, digital therapeutics, and enterprise data platforms. New Mexico, Idaho, Montana, Wyoming, Alaska, and Hawaii have smaller populations but strong need for remote neurology because distance and specialist access are major barriers.

The West is particularly important for platform economics. Providers in this region are often willing to test models that combine device hardware, remote clinical services, digital patient engagement, and outcomes-based contracting. This creates opportunities for startups, but it also raises expectations for integration and evidence. Products must work across commercial insurance, Medicare, Medicaid, employer plans, and cash-pay channels. The fastest growth will come from systems that can scale nationally after demonstrating operational success in large West Coast provider networks.

By 2035, the West will gain market share as home neurology becomes more software-defined and data-intensive. Wearable movement analytics, AI-assisted EEG, remote migraine therapy, and virtual neurorehabilitation will be the leading growth categories. California will remain the core market, while Arizona, Colorado, Washington, Utah, and Nevada will contribute disproportionately to incremental growth.

Northeast

The Northeast accounted for an estimated USD 0.64 billion in 2025 and remains the highest-value region on a per-patient and per-program basis. The region includes New York, Pennsylvania, New Jersey, Massachusetts, Connecticut, Rhode Island, New Hampshire, Vermont, and Maine. Its strength comes from a concentration of academic medical centers, epilepsy monitoring programs, movement-disorder specialists, rehabilitation institutions, clinical trials, and evidence-driven procurement committees.

New York is the largest state market in the Northeast. Large health systems in New York City and major upstate referral centers create demand for ambulatory EEG, home seizure monitoring, migraine neuromodulation, Parkinson analytics, and post-stroke rehabilitation. The state’s scale supports both premium enterprise programs and Medicaid-focused access models. Pennsylvania and New Jersey add large suburban and regional provider markets, with strong opportunity for home diagnostic services and specialty pharmacy fulfillment.

Massachusetts is strategically influential because of its academic hospitals, research institutions, biotechnology ecosystem, and willingness to evaluate emerging neurological devices. Although its population is smaller than New York or Pennsylvania, decisions made by leading Massachusetts institutions can influence clinical standards, trial design, and national adoption. Connecticut and Rhode Island support dense provider networks and high specialist access, while Maine, Vermont, and New Hampshire create opportunities for remote care across older and geographically dispersed populations.

Northeast procurement is rigorous. Hospitals and specialty centers typically require clinical validation, data security, clear escalation pathways, and evidence that home technology does not increase clinician burden. The region is also competitive because many manufacturers target the same influential institutions for pilots. Companies that succeed tend to offer research collaboration, strong medical affairs support, responsive technical service, and integration with established electronic health record systems.

The Northeast is expected to reach approximately USD 1.85 billion by 2035. Growth will be slower than the West because the market is mature and population growth is lower, but the region will remain highly profitable. Advanced ambulatory diagnostics, complex epilepsy management, movement-disorder monitoring, and academically validated digital biomarkers will be the principal value pools.

Midwest

The Midwest represented an estimated USD 0.49 billion in 2025 and is projected to reach approximately USD 1.43 billion by 2035. The region includes Illinois, Ohio, Michigan, Minnesota, Wisconsin, Indiana, Missouri, Iowa, Kansas, Nebraska, North Dakota, and South Dakota. Demand is supported by strong regional referral centers, an established medical device ecosystem, large community health systems, high stroke burden in selected states, and substantial rural access needs.

Illinois, Ohio, Michigan, and Minnesota are the major state markets. Illinois benefits from Chicago’s academic and community neurology network. Ohio has nationally recognized neurological and rehabilitation institutions and a large base of community hospitals. Michigan provides significant demand for stroke rehabilitation, movement-disorder management, and home health support. Minnesota is particularly important because of its medtech history, device engineering talent, and concentration of companies involved in neuromodulation, sensing, and chronic disease technology.

Wisconsin, Indiana, Missouri, Iowa, and Kansas offer stable demand for ambulatory diagnostics, migraine therapy, home rehabilitation, and caregiver technologies. Health systems in these states often manage broad regional catchment areas, making hub-and-spoke deployment attractive. Nebraska, North Dakota, and South Dakota are smaller markets, but remote EEG, tele-neurology-linked monitoring, and home rehabilitation can deliver high strategic value because travel distances are substantial and specialist capacity is limited.

The Midwest tends to reward vendors that provide dependable service, practical clinical education, transparent pricing, and scalable contracting. Buyers are often less interested in experimental consumer features and more focused on evidence, workflow, durability, and reimbursement. Partnerships with regional distributors, therapy networks, and home health agencies can be more effective than a purely digital direct-to-patient model.

The Midwest will remain a durable market rather than the fastest-growth region. Its strongest opportunities will be in remote diagnostics, stroke and gait rehabilitation, movement-disorder monitoring, and enterprise programs that extend academic expertise into smaller communities. Manufacturers with strong field support and a value-based selling approach can build defensible share.

Key Market Players

The U.S. Home-Based Neurology Devices Competitive Landscape is fragmented across diagnostic manufacturers, neuromodulation companies, wearable sensor specialists, rehabilitation technology firms, and digital monitoring platforms. No single company controls the entire pathway. Large medtech firms have advantages in regulatory infrastructure, contracting, implanted therapy, and provider relationships, while focused companies can lead narrow categories such as seizure wearables, migraine neuromodulation, ambulatory EEG, or Parkinson digital biomarkers.

Competition is increasingly platform-based. Manufacturers are not only selling a sensor or stimulator; they are competing on prescription access, patient onboarding, logistics, analytics, clinical review, caregiver alerts, reimbursement support, cybersecurity, and integration. The ability to maintain adherence after the first month and convert data into an actionable clinician workflow will be more important than hardware novelty alone.

Some of the key players in the U.S. Home-Based Neurology Devices industry are:

Natus Medical Incorporated
Cadwell Industries, Inc.
Nihon Kohden America, Inc.
Compumedics Limited
Philips Healthcare
GE HealthCare
Medtronic plc
Abbott Laboratories
Boston Scientific Corporation
LivaNova PLC
NeuroPace, Inc.
Empatica Inc.
Epitel, Inc.
Theranica Bio-Electronics Ltd.
CEFALY Technology
electroCore, Inc.
Neurolief Ltd.
Rune Labs, Inc.
Great Lakes NeuroTechnologies Inc.
Global Kinetics Corporation
NeuroMetrix, Inc.
Bioventus Inc. / Bioness
Myomo, Inc.
MindMaze SA
Flint Rehabilitation Devices, LLC

Natus, Cadwell, Nihon Kohden, Compumedics, Epitel, and Empatica are relevant to ambulatory neurodiagnostics and seizure monitoring. Theranica, CEFALY Technology, electroCore, and Neurolief compete in prescription or noninvasive neuromodulation for migraine and headache. Rune Labs, Great Lakes NeuroTechnologies, and Global Kinetics focus on movement-disorder measurement and digital biomarkers. Bioventus/Bioness, Myomo, MindMaze, and Flint Rehabilitation Devices participate in functional stimulation, mobility, and home neurorehabilitation. Medtronic, Abbott, Boston Scientific, LivaNova, and NeuroPace bring implanted neuromodulation, remote follow-up, or chronic neurological therapy capabilities that extend into home-centered care.

Market share through 2035 will be influenced by FDA clearance or approval, clinical evidence, reimbursement access, patient affordability, prescription-channel efficiency, data integration, battery and sensor reliability, and the ability to support large provider deployments. Consolidation is likely because home neurology requires capabilities across hardware, software, services, and medical affairs. Large companies may acquire focused platforms to gain access to digital biomarkers, home diagnostics, or patient engagement, while specialized firms will remain competitive when they own a validated clinical niche.

Recent Developments

Recent developments in the U.S. Home-Based Neurology Devices Market show that regulators and manufacturers are placing greater emphasis on home and ambulatory use. FDA-cleared seizure monitoring systems have evolved toward multimodal sensing and paired mobile software. Newer clearances for wearable seizure platforms reinforce the commercial viability of home monitoring while also highlighting the need for battery reliability, alert performance, and careful patient education.

Ambulatory EEG has also advanced. Wireless and reduced-montage systems are being evaluated for multi-day home recording, while AI-assisted tools are being used to identify or prioritize electrographic events. The market is moving toward lighter sensors and simpler logistics, but full clinical acceptance will depend on signal quality, artifact handling, and evidence that reduced montages are appropriate for the intended use.

Prescription migraine neuromodulation continued to expand through 2024 and 2025, with additional FDA clearances and product iterations for remote electrical stimulation systems. The strategic importance of these developments is broader than a single product. They validate a home-based treatment category in which patients can initiate therapy at the time of an attack, document response digitally, and reduce dependence on facility-based care or systemic medication.

Movement-disorder monitoring is becoming more integrated with common wearable technology. FDA-regulated tremor and dyskinesia measurement, software-based Parkinson monitoring, and remote review tools are creating a pathway for longitudinal management outside the clinic. The competitive focus is shifting from simple activity tracking to validated measurement of clinically meaningful motor states and treatment response.

Reimbursement policy is also evolving. Medicare continues to define remote monitoring requirements, including device data capture, patient consent, medical necessity, and clinical management. Expanded code structures increase commercial opportunity but also raise compliance expectations. Neurology vendors will need to design workflows that meet billing rules without creating excessive administrative effort or encouraging low-value monitoring.

Across the competitive landscape, manufacturers are investing in partnerships with health systems, specialty pharmacies, home health organizations, and rehabilitation networks. The market is likely to see more acquisitions of sensor, AI, and patient-engagement capabilities as larger medtech companies seek to extend neurological care beyond the hospital. Evidence generation will remain the central determinant of which innovations move from pilot programs to routine reimbursement.

Conclusion

The U.S. Home-Based Neurology Devices Market Size & Share is positioned for accelerated expansion from USD 2.68 billion in 2025 to approximately USD 8.46 billion by 2035, supported by a 12.18% CAGR during the forecast period. The market’s long-term strength is grounded in the chronic and variable nature of neurological disease, an aging population, specialist access constraints, the economic burden of facility-based care, and growing acceptance of remote monitoring and home therapy.

The most attractive growth opportunities will come from ambulatory EEG, wearable seizure detection, prescription migraine neuromodulation, Parkinson and movement-disorder analytics, functional electrical stimulation, connected stroke rehabilitation, and caregiver-facing safety platforms. Mature devices will remain important, but value creation will increasingly depend on software, interoperability, patient support, and clinically meaningful analytics. Products must show that they improve decisions or outcomes, not simply that they collect more data.

Regional opportunity will be led by the South because of population scale, aging demographics, disease burden, and rural access needs. The West will grow fastest due to digital-health adoption and innovation density. The Northeast will remain the most evidence-intensive and premium market, while the Midwest will provide a stable base for remote diagnostics, rehabilitation, and medtech partnerships. At the state level, Texas, Florida, California, New York, Pennsylvania, Massachusetts, Illinois, Ohio, Michigan, Minnesota, North Carolina, Georgia, Arizona, Washington, and Virginia will be especially important.

For clients evaluating this market, the central question is not whether neurological care will move further into the home. The more important question is which devices can convert home-generated data into trusted clinical action, fit reimbursement rules, reduce caregiver and clinician burden, and operate reliably across diverse patient populations. Companies that combine regulated hardware, evidence-based analytics, patient support, and enterprise workflow integration will define the next decade of the U.S. home-based neurology devices industry.

TABLE OF CONTENT

1. U.S. Home-Based Neurology Devices Market: Market Introduction & Context

1.1. Market Definition
1.2. Scope of the Study
1.3. Research Methodology
1.3.1. Primary Data Collection
1.3.2. Secondary Data Sourcing
1.3.3. External Industry Collaborations
1.3.4. In-House Research Databases
1.3.5. Analytical Frameworks & Forecasting Models
1.3.6. Data Validation and Final Report Publishing
1.4. Key Assumptions
1.5. Market Ecosystem Overview
1.6. Stakeholder Analysis
1.6.1. Home-Based Neurology Device Manufacturers
1.6.2. Sensor, Electrode, Semiconductor and Component Suppliers
1.6.3. Neurology Practices and Specialty Care Networks
1.6.4. Hospitals and Integrated Health Systems
1.6.5. Home Healthcare and Remote Patient Monitoring Providers
1.6.6. Durable Medical Equipment Suppliers and Specialty Distributors
1.6.7. Patients, Family Caregivers and Patient Advocacy Organizations
1.6.8. Commercial Payers, Medicare and Medicaid Programs
1.6.9. Regulators, Clinical Researchers and Technology Assessment Bodies

What this section provides: This section defines the market boundary, study scope, methodology, assumptions, and stakeholder ecosystem used to measure and validate the U.S. home-based neurology devices market.

2. U.S. Home-Based Neurology Devices Market: Executive Summary

2.1. Key Insights & Market Snapshot
2.2. Analyst Viewpoint
2.3. Market Attractiveness Index
2.4. Historical Market Summary, 2021–2024
2.5. Base Year Market Positioning, 2025
2.6. Forecast Outlook, 2026–2035
2.7. Market Size and Growth Summary, 2021–2035 (US$ Billion)
2.8. High-Growth Product and Application Areas
2.9. Key Investment and Commercialization Themes

What this section provides: This section gives decision-makers a concise view of market size, historical performance, forecast growth, major demand pockets, competitive intensity, and priority commercial opportunities.

3. U.S. Home-Based Neurology Devices Market: Market Dynamics & Outlook

3.1. Drivers and Their Impact Analysis
3.1.1. Rising Prevalence of Neurological and Neurodegenerative Disorders
3.1.2. Aging U.S. Population and Growth in Chronic Neurological Care Needs
3.1.3. Shift from Facility-Based Neurology Care to Home-Based Management
3.1.4. Expansion of Remote Patient Monitoring and Virtual Neurology Programs
3.1.5. Increasing Demand for Continuous Seizure, Movement and Cognitive Monitoring
3.1.6. Growth in Home Neurorehabilitation and Post-Stroke Recovery Programs
3.1.7. Rising Caregiver Burden and Demand for Automated Safety Alerts
3.1.8. Increasing Adoption of Connected Wearables and Digital Neurological Biomarkers
3.2. Restraints and Their Impact Analysis
3.2.1. Reimbursement Variability Across Home Neurology Device Categories
3.2.2. High Upfront Cost of Advanced Connected Neurology Devices
3.2.3. Patient Adherence and Long-Term Device Engagement Limitations
3.2.4. Clinical Accuracy and False-Alert Concerns in Unsupervised Settings
3.2.5. Data Privacy, Cybersecurity and Patient Consent Challenges
3.2.6. Digital Access and Health Literacy Gaps
3.3. Opportunities and Their Impact Analysis
3.3.1. At-Home EEG and Long-Duration Neurodiagnostic Monitoring
3.3.2. AI-Assisted Seizure and Movement Disorder Detection
3.3.3. Home-Based Stroke and Neurorehabilitation Platforms
3.3.4. Noninvasive Neuromodulation for Migraine, Pain and Movement Disorders
3.3.5. Digital Biomarkers for Parkinson’s Disease and Cognitive Decline
3.3.6. Integration with Medicare Remote Monitoring and Care Management Programs
3.3.7. Partnerships Between Device Manufacturers and Virtual Neurology Providers
3.3.8. Expansion into Rural and Neurologist-Shortage Markets
3.4. Challenges and Their Impact Analysis
3.4.1. Fragmented Neurology Care Pathways
3.4.2. Limited Interoperability with Electronic Health Records
3.4.3. Clinical Validation Requirements for Algorithm-Based Devices
3.4.4. Caregiver Training and Home-Use Usability Challenges
3.4.5. Scaling Technical Support Across Distributed Patient Populations
3.5. Patent & Innovation Analysis, 2021–2025
3.6. Clinical Workflow Economics Analysis
3.7. Home Neurology Care Cost-Savings Analysis
3.8. Health System Procurement Behavior Analysis
3.9. Patient Adoption and Device Adherence Analysis
3.10. Neurologist Workflow and Alert-Management Analysis

What this section provides: This section explains the clinical, commercial, reimbursement, behavioral, and operational forces shaping demand, enabling clients to assess growth opportunities and execution risks.

4. U.S. Home-Based Neurology Devices Market: Market Environment & Industry Analysis

4.1. PESTEL Analysis
4.1.1. Political
4.1.2. Economic
4.1.3. Social
4.1.4. Technological
4.1.5. Environmental
4.1.6. Legal
4.2. Porter’s Five Forces Analysis
4.2.1. Threat of New Entrants
4.2.2. Bargaining Power of Buyers
4.2.3. Bargaining Power of Suppliers
4.2.4. Substitution Risk
4.2.5. Competitive Rivalry
4.3. Pricing Trend Analysis by Region, 2025–2035
4.4. Value Chain & Supply Chain Analysis
4.5. Impact of Digitalization and Connected Home Neurology
4.6. Application & Innovation Landscape
4.7. FDA Regulatory Framework Analysis
4.8. FDA Human Factors and Home-Use Device Requirements
4.9. CMS Reimbursement and Coverage Landscape
4.10. Remote Physiologic Monitoring and Remote Therapeutic Monitoring Analysis
4.11. Commercial Payer Coverage and Prior Authorization Landscape
4.12. HIPAA, Cybersecurity and Neurological Data Governance
4.13. Import/Export Restrictions & Tariff Impact
4.14. Government Initiatives and Neurological Public Health Programs
4.15. Impact of Escalating Geopolitical Tensions
4.16. Home-Use Device Distribution and Fulfilment Economics
4.17. Health System and Payer Technology Assessment Framework
4.18. Patient Safety, Reliability and Post-Market Surveillance Analysis

What this section provides: This section gives clients a comprehensive view of regulation, reimbursement, pricing, supply chains, digital adoption, patient safety, data governance, and health-system purchasing dynamics.

5. U.S. Home-Based Neurology Devices Market – By Product Type

5.1. Overview
5.1.1. Segment Share Analysis, By Product Type, 2025 & 2035 (%)
5.1.2. Segment Market Size and Forecast, 2021–2035 (US$ Billion)
5.2. Home EEG and Brain Activity Monitoring Devices
5.2.1. Portable EEG Headsets
5.2.2. Ambulatory EEG Recorders
5.2.3. Dry-Electrode EEG Systems
5.2.4. Wireless EEG Monitoring Systems
5.2.5. Sleep and Brain-State Monitoring Devices
5.3. Seizure Detection and Patient Safety Devices
5.3.1. Wearable Seizure Detection Devices
5.3.2. Bed-Based Seizure Monitoring Systems
5.3.3. Video-Based Seizure Detection Systems
5.3.4. Smartwatch and Sensor-Based Seizure Alerts
5.3.5. Caregiver Notification and Emergency Alert Devices
5.4. Movement, Gait and Motor Function Monitoring Devices
5.4.1. Tremor Monitoring Devices
5.4.2. Gait and Balance Sensors
5.4.3. Bradykinesia and Dyskinesia Monitoring Devices
5.4.4. Fall Detection and Mobility Monitoring Devices
5.4.5. Upper-Limb and Fine-Motor Assessment Devices
5.5. Home Neurostimulation and Neuromodulation Devices
5.5.1. Transcutaneous Electrical Nerve Stimulation Devices
5.5.2. External Trigeminal Nerve Stimulation Devices
5.5.3. Noninvasive Vagus Nerve Stimulation Devices
5.5.4. Transcranial Electrical Stimulation Devices
5.5.5. Migraine Neuromodulation Devices
5.5.6. Home Programmers for Implantable Neuromodulation Systems
5.6. Home Neurorehabilitation and Assistive Devices
5.6.1. Robotic Rehabilitation Devices
5.6.2. Functional Electrical Stimulation Devices
5.6.3. Virtual Reality-Based Neurorehabilitation Systems
5.6.4. Hand and Upper-Limb Rehabilitation Devices
5.6.5. Gait Rehabilitation and Mobility Assistance Devices
5.6.6. Cognitive Rehabilitation Devices and Platforms

What this section provides: This section identifies the home-based neurology device categories expected to generate the strongest revenue contribution, recurring use, clinical adoption, and growth through 2035.

6. U.S. Home-Based Neurology Devices Market – By Application

6.1. Overview
6.1.1. Segment Share Analysis, By Application, 2025 & 2035 (%)
6.1.2. Segment Market Size and Forecast, 2021–2035 (US$ Billion)
6.2. Epilepsy and Seizure Management
6.2.1. Seizure Detection and Confirmation
6.2.2. Long-Term EEG Monitoring
6.2.3. Medication Response Monitoring
6.2.4. Nocturnal Seizure Surveillance
6.2.5. Sudden Unexpected Death in Epilepsy Risk Management
6.3. Parkinson’s Disease and Movement Disorders
6.3.1. Tremor and Motor-Fluctuation Monitoring
6.3.2. Gait and Balance Assessment
6.3.3. Dyskinesia and Bradykinesia Tracking
6.3.4. Medication-Timing Optimization
6.3.5. Deep Brain Stimulation Patient Management
6.4. Stroke and Post-Stroke Rehabilitation
6.4.1. Upper-Limb Motor Rehabilitation
6.4.2. Gait and Mobility Rehabilitation
6.4.3. Functional Electrical Stimulation
6.4.4. Speech and Cognitive Rehabilitation
6.4.5. Remote Therapist-Guided Rehabilitation
6.5. Alzheimer’s Disease, Dementia and Cognitive Monitoring
6.5.1. Cognitive Function Assessment
6.5.2. Activity and Behavior Monitoring
6.5.3. Wandering and Patient Safety Management
6.5.4. Sleep and Circadian Rhythm Monitoring
6.5.5. Caregiver Support and Remote Alerting
6.6. Migraine, Neuropathic Pain and Other Neurological Conditions
6.6.1. Migraine Prevention and Acute Treatment
6.6.2. Neuropathic Pain Management
6.6.3. Multiple Sclerosis Monitoring and Rehabilitation
6.6.4. Traumatic Brain Injury Monitoring
6.6.5. Neuromuscular Disorder Management
6.6.6. Sleep-Related Neurological Monitoring

What this section provides: This section helps clients understand demand by neurological condition and identify applications with strong patient volume, unmet needs, reimbursement potential, and technology adoption.

7. U.S. Home-Based Neurology Devices Market – By End User

7.1. Overview
7.1.1. Segment Share Analysis, By End User, 2025 & 2035 (%)
7.1.2. Segment Market Size and Forecast, 2021–2035 (US$ Billion)
7.2. Patients and Family Caregivers
7.2.1. Independently Managed Home Neurology Care
7.2.2. Caregiver-Assisted Monitoring
7.2.3. Direct-to-Consumer Device Users
7.3. Home Healthcare Agencies and Remote Care Providers
7.3.1. Skilled Home Health Providers
7.3.2. Remote Patient Monitoring Organizations
7.3.3. Virtual Neurology Care Providers
7.3.4. Hospital-at-Home Programs
7.4. Neurology Practices and Specialty Clinics
7.4.1. General Neurology Practices
7.4.2. Epilepsy Centers
7.4.3. Movement Disorder Clinics
7.4.4. Headache and Migraine Centers
7.4.5. Memory and Cognitive Care Clinics
7.5. Hospitals and Integrated Health Systems
7.5.1. Academic Medical Centers
7.5.2. Community Hospitals
7.5.3. Integrated Delivery Networks
7.5.4. Post-Discharge Neurology Programs
7.6. Rehabilitation Providers and Long-Term Care Organizations
7.6.1. Outpatient Rehabilitation Centers
7.6.2. Skilled Nursing Facilities
7.6.3. Assisted Living Communities
7.6.4. Long-Term Care Facilities
7.6.5. Home-Based Physical and Occupational Therapy Providers

What this section provides: This section explains which patient groups, clinical organizations, home-care providers, and rehabilitation settings will drive device purchasing, prescribing, utilization, and recurring monitoring demand.

8. U.S. Home-Based Neurology Devices Market – By Technology Type

8.1. Overview
8.1.1. Segment Share Analysis, By Technology Type, 2025 & 2035 (%)
8.1.2. Segment Market Size and Forecast, 2021–2035 (US$ Billion)
8.2. Wearable and Body-Worn Neurology Devices
8.2.1. Wrist-Worn Devices
8.2.2. Head-Worn Devices
8.2.3. Patch-Based Sensors
8.2.4. Smart Garments and Textile Sensors
8.2.5. Foot-Worn and Gait-Sensing Devices
8.3. Portable and Handheld Neurology Devices
8.3.1. Portable EEG Systems
8.3.2. Handheld Neuroassessment Devices
8.3.3. Portable Stimulation Devices
8.3.4. Tablet- and Smartphone-Enabled Assessment Systems
8.4. Noninvasive Neurostimulation Technologies
8.4.1. Electrical Nerve Stimulation
8.4.2. Trigeminal Nerve Stimulation
8.4.3. Vagus Nerve Stimulation
8.4.4. Transcranial Electrical Stimulation
8.4.5. Peripheral Nerve and Functional Electrical Stimulation
8.5. Sensor-Based and Ambient Monitoring Technologies
8.5.1. Motion and Inertial Sensors
8.5.2. Pressure and Bed Sensors
8.5.3. Video and Computer Vision Systems
8.5.4. Acoustic Monitoring Systems
8.5.5. Radar and Contactless Monitoring Technologies
8.6. Software-Enabled, AI-Assisted and Cloud-Connected Platforms
8.6.1. AI-Based Seizure Detection Algorithms
8.6.2. Digital Biomarker Platforms
8.6.3. Cloud-Based Neurology Dashboards
8.6.4. Mobile Neurology Applications
8.6.5. Predictive Analytics and Clinical Decision Support
8.6.6. Electronic Health Record and Telehealth Integration

What this section provides: This section evaluates the wearable, portable, stimulation, sensor, cloud, and artificial intelligence technologies shaping home-based neurological diagnosis, monitoring, treatment, and rehabilitation.

9. U.S. Home-Based Neurology Devices Market – By Procurement Channel

9.1. Overview
9.1.1. Segment Share Analysis, By Procurement Channel, 2025 & 2035 (%)
9.1.2. Segment Market Size and Forecast, 2021–2035 (US$ Billion)
9.2. Direct-to-Consumer and Manufacturer E-Commerce
9.2.1. Manufacturer-Owned Online Channels
9.2.2. Subscription-Based Device Programs
9.2.3. Consumer-Purchased Neurological Wearables
9.3. Hospital and Health System Home-Care Programs
9.3.1. Integrated Delivery Network Contracts
9.3.2. Hospital-at-Home Procurement
9.3.3. Post-Discharge Device Programs
9.3.4. Enterprise Remote Monitoring Contracts
9.4. Neurology Practice and Specialty Clinic Prescribing
9.4.1. Physician-Prescribed Home Monitoring Devices
9.4.2. Clinic-Dispensed Neurostimulation Devices
9.4.3. Diagnostic Service and Device Bundles
9.5. Home Healthcare, DME and Specialty Distributor Channels
9.5.1. Durable Medical Equipment Suppliers
9.5.2. Home Healthcare Agency Procurement
9.5.3. Specialty Neurology Device Distributors
9.5.4. Rehabilitation Equipment Suppliers
9.6. Retail Pharmacy and Digital Health Marketplace Channels
9.6.1. Retail Pharmacy Networks
9.6.2. Online Healthcare Marketplaces
9.6.3. Employer and Health Plan Digital Formularies
9.6.4. Payer-Sponsored Device Distribution Programs

What this section provides: This section explains how home-based neurology devices are prescribed, purchased, reimbursed, distributed, and delivered through consumer, clinical, health-system, DME, retail, and digital channels.

10. U.S. Home-Based Neurology Devices Market – By Geography

10.1. Introduction
10.1.1. Segment Share Analysis, By Geography, 2025 & 2035 (%)
10.1.2. Regional Market Size and Forecast, 2021–2035 (US$ Billion)
10.1.3. Regional Neurological Disease Burden Analysis
10.1.4. Regional Aging Population and Home-Care Demand Analysis
10.1.5. Regional Neurologist Availability and Care Access Analysis
10.1.6. Regional Remote Monitoring and Telehealth Adoption Analysis
10.1.7. Regional Reimbursement and Procurement Dynamics

10.2. West Region

10.2.1. Regional Overview & Trends
10.2.2. West Region Key Manufacturers, Digital Health Innovators and Procurement Ecosystem
10.2.3. West Region Market Size and Forecast, By State, 2021–2035 (US$ Billion)
10.2.4. West Region Market Size and Forecast, By Product Type, 2021–2035 (US$ Billion)
10.2.5. West Region Market Size and Forecast, By Application, 2021–2035 (US$ Billion)
10.2.6. West Region Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.2.7. West Region Market Size and Forecast, By Technology Type, 2021–2035 (US$ Billion)
10.2.8. West Region Market Size and Forecast, By Procurement Channel, 2021–2035 (US$ Billion)

10.2.9. California
10.2.9.1. Overview
10.2.9.2. California Market Size and Forecast, By Product Type, 2021–2035 (US$ Billion)
10.2.9.3. California Market Size and Forecast, By Application, 2021–2035 (US$ Billion)
10.2.9.4. California Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.2.9.5. California Market Size and Forecast, By Technology Type, 2021–2035 (US$ Billion)
10.2.9.6. California Market Size and Forecast, By Procurement Channel, 2021–2035 (US$ Billion)

10.2.10. Washington
10.2.10.1. Overview
10.2.10.2. Washington Market Size and Forecast, By Product Type, 2021–2035 (US$ Billion)
10.2.10.3. Washington Market Size and Forecast, By Application, 2021–2035 (US$ Billion)
10.2.10.4. Washington Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.2.10.5. Washington Market Size and Forecast, By Technology Type, 2021–2035 (US$ Billion)
10.2.10.6. Washington Market Size and Forecast, By Procurement Channel, 2021–2035 (US$ Billion)

10.2.11. Arizona
10.2.11.1. Overview
10.2.11.2. Arizona Market Size and Forecast, By Product Type, 2021–2035 (US$ Billion)
10.2.11.3. Arizona Market Size and Forecast, By Application, 2021–2035 (US$ Billion)
10.2.11.4. Arizona Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.2.11.5. Arizona Market Size and Forecast, By Technology Type, 2021–2035 (US$ Billion)
10.2.11.6. Arizona Market Size and Forecast, By Procurement Channel, 2021–2035 (US$ Billion)

10.2.12. Colorado
10.2.12.1. Overview
10.2.12.2. Colorado Market Size and Forecast, By Product Type, 2021–2035 (US$ Billion)
10.2.12.3. Colorado Market Size and Forecast, By Application, 2021–2035 (US$ Billion)
10.2.12.4. Colorado Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.2.12.5. Colorado Market Size and Forecast, By Technology Type, 2021–2035 (US$ Billion)
10.2.12.6. Colorado Market Size and Forecast, By Procurement Channel, 2021–2035 (US$ Billion)

10.2.13. Oregon
10.2.13.1. Overview
10.2.13.2. Oregon Market Size and Forecast, By Product Type, 2021–2035 (US$ Billion)
10.2.13.3. Oregon Market Size and Forecast, By Application, 2021–2035 (US$ Billion)
10.2.13.4. Oregon Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.2.13.5. Oregon Market Size and Forecast, By Technology Type, 2021–2035 (US$ Billion)
10.2.13.6. Oregon Market Size and Forecast, By Procurement Channel, 2021–2035 (US$ Billion)

10.2.14. Utah
10.2.14.1. Overview
10.2.14.2. Utah Market Size and Forecast, By Product Type, 2021–2035 (US$ Billion)
10.2.14.3. Utah Market Size and Forecast, By Application, 2021–2035 (US$ Billion)
10.2.14.4. Utah Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.2.14.5. Utah Market Size and Forecast, By Technology Type, 2021–2035 (US$ Billion)
10.2.14.6. Utah Market Size and Forecast, By Procurement Channel, 2021–2035 (US$ Billion)

10.2.15. Nevada
10.2.15.1. Overview
10.2.15.2. Nevada Market Size and Forecast, By Product Type, 2021–2035 (US$ Billion)
10.2.15.3. Nevada Market Size and Forecast, By Application, 2021–2035 (US$ Billion)
10.2.15.4. Nevada Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.2.15.5. Nevada Market Size and Forecast, By Technology Type, 2021–2035 (US$ Billion)
10.2.15.6. Nevada Market Size and Forecast, By Procurement Channel, 2021–2035 (US$ Billion)

10.2.16. New Mexico
10.2.16.1. Overview
10.2.16.2. New Mexico Market Size and Forecast, By Product Type, 2021–2035 (US$ Billion)
10.2.16.3. New Mexico Market Size and Forecast, By Application, 2021–2035 (US$ Billion)
10.2.16.4. New Mexico Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.2.16.5. New Mexico Market Size and Forecast, By Technology Type, 2021–2035 (US$ Billion)
10.2.16.6. New Mexico Market Size and Forecast, By Procurement Channel, 2021–2035 (US$ Billion)

10.2.17. Idaho
10.2.17.1. Overview
10.2.17.2. Idaho Market Size and Forecast, By Product Type, 2021–2035 (US$ Billion)
10.2.17.3. Idaho Market Size and Forecast, By Application, 2021–2035 (US$ Billion)
10.2.17.4. Idaho Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.2.17.5. Idaho Market Size and Forecast, By Technology Type, 2021–2035 (US$ Billion)
10.2.17.6. Idaho Market Size and Forecast, By Procurement Channel, 2021–2035 (US$ Billion)

10.2.18. Montana
10.2.18.1. Overview
10.2.18.2. Montana Market Size and Forecast, By Product Type, 2021–2035 (US$ Billion)
10.2.18.3. Montana Market Size and Forecast, By Application, 2021–2035 (US$ Billion)
10.2.18.4. Montana Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.2.18.5. Montana Market Size and Forecast, By Technology Type, 2021–2035 (US$ Billion)
10.2.18.6. Montana Market Size and Forecast, By Procurement Channel, 2021–2035 (US$ Billion)

10.2.19. Wyoming
10.2.19.1. Overview
10.2.19.2. Wyoming Market Size and Forecast, By Product Type, 2021–2035 (US$ Billion)
10.2.19.3. Wyoming Market Size and Forecast, By Application, 2021–2035 (US$ Billion)
10.2.19.4. Wyoming Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.2.19.5. Wyoming Market Size and Forecast, By Technology Type, 2021–2035 (US$ Billion)
10.2.19.6. Wyoming Market Size and Forecast, By Procurement Channel, 2021–2035 (US$ Billion)

10.2.20. Alaska
10.2.20.1. Overview
10.2.20.2. Alaska Market Size and Forecast, By Product Type, 2021–2035 (US$ Billion)
10.2.20.3. Alaska Market Size and Forecast, By Application, 2021–2035 (US$ Billion)
10.2.20.4. Alaska Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.2.20.5. Alaska Market Size and Forecast, By Technology Type, 2021–2035 (US$ Billion)
10.2.20.6. Alaska Market Size and Forecast, By Procurement Channel, 2021–2035 (US$ Billion)

10.2.21. Hawaii
10.2.21.1. Overview
10.2.21.2. Hawaii Market Size and Forecast, By Product Type, 2021–2035 (US$ Billion)
10.2.21.3. Hawaii Market Size and Forecast, By Application, 2021–2035 (US$ Billion)
10.2.21.4. Hawaii Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.2.21.5. Hawaii Market Size and Forecast, By Technology Type, 2021–2035 (US$ Billion)
10.2.21.6. Hawaii Market Size and Forecast, By Procurement Channel, 2021–2035 (US$ Billion)

10.3. Northeast Region

10.3.1. Regional Overview & Trends
10.3.2. Northeast Region Key Manufacturers, Neurology Centers and Procurement Ecosystem
10.3.3. Northeast Region Market Size and Forecast, By State, 2021–2035 (US$ Billion)
10.3.4. Northeast Region Market Size and Forecast, By Product Type, 2021–2035 (US$ Billion)
10.3.5. Northeast Region Market Size and Forecast, By Application, 2021–2035 (US$ Billion)
10.3.6. Northeast Region Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.3.7. Northeast Region Market Size and Forecast, By Technology Type, 2021–2035 (US$ Billion)
10.3.8. Northeast Region Market Size and Forecast, By Procurement Channel, 2021–2035 (US$ Billion)

10.3.9. New York
10.3.9.1. Overview
10.3.9.2. New York Market Size and Forecast, By Product Type, 2021–2035 (US$ Billion)
10.3.9.3. New York Market Size and Forecast, By Application, 2021–2035 (US$ Billion)
10.3.9.4. New York Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.3.9.5. New York Market Size and Forecast, By Technology Type, 2021–2035 (US$ Billion)
10.3.9.6. New York Market Size and Forecast, By Procurement Channel, 2021–2035 (US$ Billion)

10.3.10. Massachusetts
10.3.10.1. Overview
10.3.10.2. Massachusetts Market Size and Forecast, By Product Type, 2021–2035 (US$ Billion)
10.3.10.3. Massachusetts Market Size and Forecast, By Application, 2021–2035 (US$ Billion)
10.3.10.4. Massachusetts Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.3.10.5. Massachusetts Market Size and Forecast, By Technology Type, 2021–2035 (US$ Billion)
10.3.10.6. Massachusetts Market Size and Forecast, By Procurement Channel, 2021–2035 (US$ Billion)

10.3.11. New Jersey
10.3.11.1. Overview
10.3.11.2. New Jersey Market Size and Forecast, By Product Type, 2021–2035 (US$ Billion)
10.3.11.3. New Jersey Market Size and Forecast, By Application, 2021–2035 (US$ Billion)
10.3.11.4. New Jersey Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.3.11.5. New Jersey Market Size and Forecast, By Technology Type, 2021–2035 (US$ Billion)
10.3.11.6. New Jersey Market Size and Forecast, By Procurement Channel, 2021–2035 (US$ Billion)

10.3.12. Pennsylvania
10.3.12.1. Overview
10.3.12.2. Pennsylvania Market Size and Forecast, By Product Type, 2021–2035 (US$ Billion)
10.3.12.3. Pennsylvania Market Size and Forecast, By Application, 2021–2035 (US$ Billion)
10.3.12.4. Pennsylvania Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.3.12.5. Pennsylvania Market Size and Forecast, By Technology Type, 2021–2035 (US$ Billion)
10.3.12.6. Pennsylvania Market Size and Forecast, By Procurement Channel, 2021–2035 (US$ Billion)

10.3.13. Connecticut
10.3.13.1. Overview
10.3.13.2. Connecticut Market Size and Forecast, By Product Type, 2021–2035 (US$ Billion)
10.3.13.3. Connecticut Market Size and Forecast, By Application, 2021–2035 (US$ Billion)
10.3.13.4. Connecticut Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.3.13.5. Connecticut Market Size and Forecast, By Technology Type, 2021–2035 (US$ Billion)
10.3.13.6. Connecticut Market Size and Forecast, By Procurement Channel, 2021–2035 (US$ Billion)

10.3.14. Maine
10.3.14.1. Overview
10.3.14.2. Maine Market Size and Forecast, By Product Type, 2021–2035 (US$ Billion)
10.3.14.3. Maine Market Size and Forecast, By Application, 2021–2035 (US$ Billion)
10.3.14.4. Maine Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.3.14.5. Maine Market Size and Forecast, By Technology Type, 2021–2035 (US$ Billion)
10.3.14.6. Maine Market Size and Forecast, By Procurement Channel, 2021–2035 (US$ Billion)

10.3.15. Vermont
10.3.15.1. Overview
10.3.15.2. Vermont Market Size and Forecast, By Product Type, 2021–2035 (US$ Billion)
10.3.15.3. Vermont Market Size and Forecast, By Application, 2021–2035 (US$ Billion)
10.3.15.4. Vermont Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.3.15.5. Vermont Market Size and Forecast, By Technology Type, 2021–2035 (US$ Billion)
10.3.15.6. Vermont Market Size and Forecast, By Procurement Channel, 2021–2035 (US$ Billion)

10.3.16. New Hampshire
10.3.16.1. Overview
10.3.16.2. New Hampshire Market Size and Forecast, By Product Type, 2021–2035 (US$ Billion)
10.3.16.3. New Hampshire Market Size and Forecast, By Application, 2021–2035 (US$ Billion)
10.3.16.4. New Hampshire Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.3.16.5. New Hampshire Market Size and Forecast, By Technology Type, 2021–2035 (US$ Billion)
10.3.16.6. New Hampshire Market Size and Forecast, By Procurement Channel, 2021–2035 (US$ Billion)

10.3.17. Rhode Island
10.3.17.1. Overview
10.3.17.2. Rhode Island Market Size and Forecast, By Product Type, 2021–2035 (US$ Billion)
10.3.17.3. Rhode Island Market Size and Forecast, By Application, 2021–2035 (US$ Billion)
10.3.17.4. Rhode Island Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.3.17.5. Rhode Island Market Size and Forecast, By Technology Type, 2021–2035 (US$ Billion)
10.3.17.6. Rhode Island Market Size and Forecast, By Procurement Channel, 2021–2035 (US$ Billion)

10.3.18. Delaware
10.3.18.1. Overview
10.3.18.2. Delaware Market Size and Forecast, By Product Type, 2021–2035 (US$ Billion)
10.3.18.3. Delaware Market Size and Forecast, By Application, 2021–2035 (US$ Billion)
10.3.18.4. Delaware Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.3.18.5. Delaware Market Size and Forecast, By Technology Type, 2021–2035 (US$ Billion)
10.3.18.6. Delaware Market Size and Forecast, By Procurement Channel, 2021–2035 (US$ Billion)

10.4. South Region

10.4.1. Regional Overview & Trends
10.4.2. South Region Key Manufacturers, Home-Care Providers and Procurement Ecosystem
10.4.3. South Region Market Size and Forecast, By State, 2021–2035 (US$ Billion)
10.4.4. South Region Market Size and Forecast, By Product Type, 2021–2035 (US$ Billion)
10.4.5. South Region Market Size and Forecast, By Application, 2021–2035 (US$ Billion)
10.4.6. South Region Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.4.7. South Region Market Size and Forecast, By Technology Type, 2021–2035 (US$ Billion)
10.4.8. South Region Market Size and Forecast, By Procurement Channel, 2021–2035 (US$ Billion)

10.4.9. Texas
10.4.9.1. Overview
10.4.9.2. Texas Market Size and Forecast, By Product Type, 2021–2035 (US$ Billion)
10.4.9.3. Texas Market Size and Forecast, By Application, 2021–2035 (US$ Billion)
10.4.9.4. Texas Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.4.9.5. Texas Market Size and Forecast, By Technology Type, 2021–2035 (US$ Billion)
10.4.9.6. Texas Market Size and Forecast, By Procurement Channel, 2021–2035 (US$ Billion)

10.4.10. Florida
10.4.10.1. Overview
10.4.10.2. Florida Market Size and Forecast, By Product Type, 2021–2035 (US$ Billion)
10.4.10.3. Florida Market Size and Forecast, By Application, 2021–2035 (US$ Billion)
10.4.10.4. Florida Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.4.10.5. Florida Market Size and Forecast, By Technology Type, 2021–2035 (US$ Billion)
10.4.10.6. Florida Market Size and Forecast, By Procurement Channel, 2021–2035 (US$ Billion)

10.4.11. Georgia
10.4.11.1. Overview
10.4.11.2. Georgia Market Size and Forecast, By Product Type, 2021–2035 (US$ Billion)
10.4.11.3. Georgia Market Size and Forecast, By Application, 2021–2035 (US$ Billion)
10.4.11.4. Georgia Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.4.11.5. Georgia Market Size and Forecast, By Technology Type, 2021–2035 (US$ Billion)
10.4.11.6. Georgia Market Size and Forecast, By Procurement Channel, 2021–2035 (US$ Billion)

10.4.12. North Carolina
10.4.12.1. Overview
10.4.12.2. North Carolina Market Size and Forecast, By Product Type, 2021–2035 (US$ Billion)
10.4.12.3. North Carolina Market Size and Forecast, By Application, 2021–2035 (US$ Billion)
10.4.12.4. North Carolina Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.4.12.5. North Carolina Market Size and Forecast, By Technology Type, 2021–2035 (US$ Billion)
10.4.12.6. North Carolina Market Size and Forecast, By Procurement Channel, 2021–2035 (US$ Billion)

10.4.13. Tennessee
10.4.13.1. Overview
10.4.13.2. Tennessee Market Size and Forecast, By Product Type, 2021–2035 (US$ Billion)
10.4.13.3. Tennessee Market Size and Forecast, By Application, 2021–2035 (US$ Billion)
10.4.13.4. Tennessee Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.4.13.5. Tennessee Market Size and Forecast, By Technology Type, 2021–2035 (US$ Billion)
10.4.13.6. Tennessee Market Size and Forecast, By Procurement Channel, 2021–2035 (US$ Billion)

10.4.14. South Carolina
10.4.14.1. Overview
10.4.14.2. South Carolina Market Size and Forecast, By Product Type, 2021–2035 (US$ Billion)
10.4.14.3. South Carolina Market Size and Forecast, By Application, 2021–2035 (US$ Billion)
10.4.14.4. South Carolina Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.4.14.5. South Carolina Market Size and Forecast, By Technology Type, 2021–2035 (US$ Billion)
10.4.14.6. South Carolina Market Size and Forecast, By Procurement Channel, 2021–2035 (US$ Billion)

10.4.15. Alabama
10.4.15.1. Overview
10.4.15.2. Alabama Market Size and Forecast, By Product Type, 2021–2035 (US$ Billion)
10.4.15.3. Alabama Market Size and Forecast, By Application, 2021–2035 (US$ Billion)
10.4.15.4. Alabama Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.4.15.5. Alabama Market Size and Forecast, By Technology Type, 2021–2035 (US$ Billion)
10.4.15.6. Alabama Market Size and Forecast, By Procurement Channel, 2021–2035 (US$ Billion)

10.4.16. Mississippi
10.4.16.1. Overview
10.4.16.2. Mississippi Market Size and Forecast, By Product Type, 2021–2035 (US$ Billion)
10.4.16.3. Mississippi Market Size and Forecast, By Application, 2021–2035 (US$ Billion)
10.4.16.4. Mississippi Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.4.16.5. Mississippi Market Size and Forecast, By Technology Type, 2021–2035 (US$ Billion)
10.4.16.6. Mississippi Market Size and Forecast, By Procurement Channel, 2021–2035 (US$ Billion)

10.4.17. Louisiana
10.4.17.1. Overview
10.4.17.2. Louisiana Market Size and Forecast, By Product Type, 2021–2035 (US$ Billion)
10.4.17.3. Louisiana Market Size and Forecast, By Application, 2021–2035 (US$ Billion)
10.4.17.4. Louisiana Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.4.17.5. Louisiana Market Size and Forecast, By Technology Type, 2021–2035 (US$ Billion)
10.4.17.6. Louisiana Market Size and Forecast, By Procurement Channel, 2021–2035 (US$ Billion)

10.4.18. Arkansas
10.4.18.1. Overview
10.4.18.2. Arkansas Market Size and Forecast, By Product Type, 2021–2035 (US$ Billion)
10.4.18.3. Arkansas Market Size and Forecast, By Application, 2021–2035 (US$ Billion)
10.4.18.4. Arkansas Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.4.18.5. Arkansas Market Size and Forecast, By Technology Type, 2021–2035 (US$ Billion)
10.4.18.6. Arkansas Market Size and Forecast, By Procurement Channel, 2021–2035 (US$ Billion)

10.4.19. Kentucky
10.4.19.1. Overview
10.4.19.2. Kentucky Market Size and Forecast, By Product Type, 2021–2035 (US$ Billion)
10.4.19.3. Kentucky Market Size and Forecast, By Application, 2021–2035 (US$ Billion)
10.4.19.4. Kentucky Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.4.19.5. Kentucky Market Size and Forecast, By Technology Type, 2021–2035 (US$ Billion)
10.4.19.6. Kentucky Market Size and Forecast, By Procurement Channel, 2021–2035 (US$ Billion)

10.4.20. Oklahoma
10.4.20.1. Overview
10.4.20.2. Oklahoma Market Size and Forecast, By Product Type, 2021–2035 (US$ Billion)
10.4.20.3. Oklahoma Market Size and Forecast, By Application, 2021–2035 (US$ Billion)
10.4.20.4. Oklahoma Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.4.20.5. Oklahoma Market Size and Forecast, By Technology Type, 2021–2035 (US$ Billion)
10.4.20.6. Oklahoma Market Size and Forecast, By Procurement Channel, 2021–2035 (US$ Billion)

10.4.21. Virginia
10.4.21.1. Overview
10.4.21.2. Virginia Market Size and Forecast, By Product Type, 2021–2035 (US$ Billion)
10.4.21.3. Virginia Market Size and Forecast, By Application, 2021–2035 (US$ Billion)
10.4.21.4. Virginia Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.4.21.5. Virginia Market Size and Forecast, By Technology Type, 2021–2035 (US$ Billion)
10.4.21.6. Virginia Market Size and Forecast, By Procurement Channel, 2021–2035 (US$ Billion)

10.4.22. Maryland
10.4.22.1. Overview
10.4.22.2. Maryland Market Size and Forecast, By Product Type, 2021–2035 (US$ Billion)
10.4.22.3. Maryland Market Size and Forecast, By Application, 2021–2035 (US$ Billion)
10.4.22.4. Maryland Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.4.22.5. Maryland Market Size and Forecast, By Technology Type, 2021–2035 (US$ Billion)
10.4.22.6. Maryland Market Size and Forecast, By Procurement Channel, 2021–2035 (US$ Billion)

10.4.23. West Virginia
10.4.23.1. Overview
10.4.23.2. West Virginia Market Size and Forecast, By Product Type, 2021–2035 (US$ Billion)
10.4.23.3. West Virginia Market Size and Forecast, By Application, 2021–2035 (US$ Billion)
10.4.23.4. West Virginia Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.4.23.5. West Virginia Market Size and Forecast, By Technology Type, 2021–2035 (US$ Billion)
10.4.23.6. West Virginia Market Size and Forecast, By Procurement Channel, 2021–2035 (US$ Billion)

10.5. Midwest Region

10.5.1. Regional Overview & Trends
10.5.2. Midwest Region Key Manufacturers, Rehabilitation Networks and Procurement Ecosystem
10.5.3. Midwest Region Market Size and Forecast, By State, 2021–2035 (US$ Billion)
10.5.4. Midwest Region Market Size and Forecast, By Product Type, 2021–2035 (US$ Billion)
10.5.5. Midwest Region Market Size and Forecast, By Application, 2021–2035 (US$ Billion)
10.5.6. Midwest Region Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.5.7. Midwest Region Market Size and Forecast, By Technology Type, 2021–2035 (US$ Billion)
10.5.8. Midwest Region Market Size and Forecast, By Procurement Channel, 2021–2035 (US$ Billion)

10.5.9. Illinois
10.5.9.1. Overview
10.5.9.2. Illinois Market Size and Forecast, By Product Type, 2021–2035 (US$ Billion)
10.5.9.3. Illinois Market Size and Forecast, By Application, 2021–2035 (US$ Billion)
10.5.9.4. Illinois Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.5.9.5. Illinois Market Size and Forecast, By Technology Type, 2021–2035 (US$ Billion)
10.5.9.6. Illinois Market Size and Forecast, By Procurement Channel, 2021–2035 (US$ Billion)

10.5.10. Ohio
10.5.10.1. Overview
10.5.10.2. Ohio Market Size and Forecast, By Product Type, 2021–2035 (US$ Billion)
10.5.10.3. Ohio Market Size and Forecast, By Application, 2021–2035 (US$ Billion)
10.5.10.4. Ohio Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.5.10.5. Ohio Market Size and Forecast, By Technology Type, 2021–2035 (US$ Billion)
10.5.10.6. Ohio Market Size and Forecast, By Procurement Channel, 2021–2035 (US$ Billion)

10.5.11. Michigan
10.5.11.1. Overview
10.5.11.2. Michigan Market Size and Forecast, By Product Type, 2021–2035 (US$ Billion)
10.5.11.3. Michigan Market Size and Forecast, By Application, 2021–2035 (US$ Billion)
10.5.11.4. Michigan Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.5.11.5. Michigan Market Size and Forecast, By Technology Type, 2021–2035 (US$ Billion)
10.5.11.6. Michigan Market Size and Forecast, By Procurement Channel, 2021–2035 (US$ Billion)

10.5.12. Minnesota
10.5.12.1. Overview
10.5.12.2. Minnesota Market Size and Forecast, By Product Type, 2021–2035 (US$ Billion)
10.5.12.3. Minnesota Market Size and Forecast, By Application, 2021–2035 (US$ Billion)
10.5.12.4. Minnesota Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.5.12.5. Minnesota Market Size and Forecast, By Technology Type, 2021–2035 (US$ Billion)
10.5.12.6. Minnesota Market Size and Forecast, By Procurement Channel, 2021–2035 (US$ Billion)

10.5.13. Indiana
10.5.13.1. Overview
10.5.13.2. Indiana Market Size and Forecast, By Product Type, 2021–2035 (US$ Billion)
10.5.13.3. Indiana Market Size and Forecast, By Application, 2021–2035 (US$ Billion)
10.5.13.4. Indiana Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.5.13.5. Indiana Market Size and Forecast, By Technology Type, 2021–2035 (US$ Billion)
10.5.13.6. Indiana Market Size and Forecast, By Procurement Channel, 2021–2035 (US$ Billion)

10.5.14. Wisconsin
10.5.14.1. Overview
10.5.14.2. Wisconsin Market Size and Forecast, By Product Type, 2021–2035 (US$ Billion)
10.5.14.3. Wisconsin Market Size and Forecast, By Application, 2021–2035 (US$ Billion)
10.5.14.4. Wisconsin Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.5.14.5. Wisconsin Market Size and Forecast, By Technology Type, 2021–2035 (US$ Billion)
10.5.14.6. Wisconsin Market Size and Forecast, By Procurement Channel, 2021–2035 (US$ Billion)

10.5.15. Missouri
10.5.15.1. Overview
10.5.15.2. Missouri Market Size and Forecast, By Product Type, 2021–2035 (US$ Billion)
10.5.15.3. Missouri Market Size and Forecast, By Application, 2021–2035 (US$ Billion)
10.5.15.4. Missouri Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.5.15.5. Missouri Market Size and Forecast, By Technology Type, 2021–2035 (US$ Billion)
10.5.15.6. Missouri Market Size and Forecast, By Procurement Channel, 2021–2035 (US$ Billion)

10.5.16. Iowa
10.5.16.1. Overview
10.5.16.2. Iowa Market Size and Forecast, By Product Type, 2021–2035 (US$ Billion)
10.5.16.3. Iowa Market Size and Forecast, By Application, 2021–2035 (US$ Billion)
10.5.16.4. Iowa Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.5.16.5. Iowa Market Size and Forecast, By Technology Type, 2021–2035 (US$ Billion)
10.5.16.6. Iowa Market Size and Forecast, By Procurement Channel, 2021–2035 (US$ Billion)

10.5.17. Kansas
10.5.17.1. Overview
10.5.17.2. Kansas Market Size and Forecast, By Product Type, 2021–2035 (US$ Billion)
10.5.17.3. Kansas Market Size and Forecast, By Application, 2021–2035 (US$ Billion)
10.5.17.4. Kansas Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.5.17.5. Kansas Market Size and Forecast, By Technology Type, 2021–2035 (US$ Billion)
10.5.17.6. Kansas Market Size and Forecast, By Procurement Channel, 2021–2035 (US$ Billion)

10.5.18. Nebraska
10.5.18.1. Overview
10.5.18.2. Nebraska Market Size and Forecast, By Product Type, 2021–2035 (US$ Billion)
10.5.18.3. Nebraska Market Size and Forecast, By Application, 2021–2035 (US$ Billion)
10.5.18.4. Nebraska Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.5.18.5. Nebraska Market Size and Forecast, By Technology Type, 2021–2035 (US$ Billion)
10.5.18.6. Nebraska Market Size and Forecast, By Procurement Channel, 2021–2035 (US$ Billion)

10.5.19. North Dakota
10.5.19.1. Overview
10.5.19.2. North Dakota Market Size and Forecast, By Product Type, 2021–2035 (US$ Billion)
10.5.19.3. North Dakota Market Size and Forecast, By Application, 2021–2035 (US$ Billion)
10.5.19.4. North Dakota Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.5.19.5. North Dakota Market Size and Forecast, By Technology Type, 2021–2035 (US$ Billion)
10.5.19.6. North Dakota Market Size and Forecast, By Procurement Channel, 2021–2035 (US$ Billion)

10.5.20. South Dakota
10.5.20.1. Overview
10.5.20.2. South Dakota Market Size and Forecast, By Product Type, 2021–2035 (US$ Billion)
10.5.20.3. South Dakota Market Size and Forecast, By Application, 2021–2035 (US$ Billion)
10.5.20.4. South Dakota Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.5.20.5. South Dakota Market Size and Forecast, By Technology Type, 2021–2035 (US$ Billion)
10.5.20.6. South Dakota Market Size and Forecast, By Procurement Channel, 2021–2035 (US$ Billion)

What this section provides: This section delivers detailed regional and state-level analysis, helping clients identify priority geographies, neurological care-access gaps, aging-population demand centers, remote monitoring adoption hotspots, and state-level commercial opportunities.

11. U.S. Home-Based Neurology Devices Market: Competitive Landscape & Company Profiles

11.1. Market Share Analysis, 2025
11.2. Competitive Benchmarking
11.2.1. Product Portfolio Breadth
11.2.2. Home-Use Regulatory Positioning
11.2.3. Clinical Evidence Strength
11.2.4. Connectivity and Digital Platform Capabilities
11.2.5. Reimbursement and Market Access Support
11.2.6. Distribution and Patient-Support Infrastructure
11.3. Company Positioning Matrix
11.3.1. Leaders
11.3.2. Challengers
11.3.3. Innovators
11.3.4. Emerging Players
11.4. Company Profiles
11.4.1. Medtronic
11.4.2. Abbott Laboratories
11.4.3. Boston Scientific Corporation
11.4.4. LivaNova
11.4.5. NeuroPace
11.4.6. NeuroMetrix
11.4.7. electroCore
11.4.8. CEFALY Technology
11.4.9. Natus Medical Incorporated
11.4.10. Zeto
11.4.11. Compumedics
11.4.12. Empatica
11.4.13. Smart Monitor Corporation
11.4.14. Seer Medical
11.4.15. Rune Labs
11.4.16. Koneksa Health
11.4.17. MindMaze
11.4.18. DIH/Hocoma
11.4.19. ReWalk Robotics
11.4.20. Ekso Bionics
11.4.21. Bioness
11.4.22. Neofect
11.4.23. Flint Rehabilitation Devices
11.4.24. Constant Therapy Health
11.4.25. Neurolutions

Note: Each company profile will include company overview, home-based neurology device portfolio, U.S. market strategy, financial and commercial positioning, clinical evidence, regulatory status, digital capabilities, partnerships, reimbursement initiatives, and recent developments.

What this section provides: This section gives clients competitor benchmarking, market-share visibility, portfolio positioning, technology differentiation, clinical-evidence assessment, and strategic intelligence on major home-based neurology device companies.

12. U.S. Home-Based Neurology Devices Market: Future Market Outlook, 2026–2035

12.1. Scenario Analysis
12.1.1. Optimistic Scenario
12.1.2. Realistic Scenario
12.1.3. Pessimistic Scenario
12.2. Disruptive Technologies Impact
12.2.1. At-Home EEG and Continuous Brain Monitoring
12.2.2. AI-Assisted Neurological Digital Biomarkers
12.2.3. Predictive Seizure and Fall Detection
12.2.4. Closed-Loop and Personalized Neuromodulation
12.2.5. Virtual Reality and Robotic Neurorehabilitation
12.2.6. Contactless and Ambient Neurological Monitoring
12.2.7. Multimodal Sensor Fusion and Digital Phenotyping
12.2.8. Voice, Speech and Cognitive Biomarker Technologies
12.3. Emerging Business Trends
12.3.1. Device-as-a-Service Business Models
12.3.2. Subscription-Based Monitoring Programs
12.3.3. Manufacturer–Provider Risk-Sharing Agreements
12.3.4. Decentralized Neurology Clinical Trials
12.3.5. Consumerization of Neurological Monitoring
12.4. Business Opportunities for Startups and Existing Players
12.5. Investment Prioritization Matrix
12.6. Product Commercialization Readiness Framework
12.7. Reimbursement Expansion Outlook
12.8. Long-Term Market Consolidation Outlook

What this section provides: This section prepares clients for future technology shifts, reimbursement developments, changing business models, market consolidation, and adoption scenarios through 2035.

13. U.S. Home-Based Neurology Devices Market: Strategic Recommendations

13.1. Recommendations for Device Manufacturers
13.2. Recommendations for Hospitals and Integrated Health Systems
13.3. Recommendations for Neurology Practices and Specialty Clinics
13.4. Recommendations for Home Healthcare and Remote Monitoring Providers
13.5. Recommendations for Investors and Private Equity Firms
13.6. Recommendations for Distributors and Channel Partners
13.7. Recommendations for Commercial Payers and Medicare-Focused Organizations
13.8. Recommendations for New Entrants and Startups
13.9. Go-to-Market Strategy Considerations
13.10. Product Positioning and Portfolio Expansion Guidance
13.11. Clinical Evidence and Regulatory Strategy
13.12. Reimbursement and Health Economics Strategy
13.13. Patient Engagement and Adherence Strategy
13.14. Partnership, Licensing and Acquisition Opportunities

What this section provides: This section converts market intelligence into actionable recommendations for product development, evidence generation, market access, channel expansion, investment planning, patient engagement, and competitive differentiation.

14. U.S. Home-Based Neurology Devices Market: Disclaimer

14.1. Scope Limitation
14.2. Data Use Limitation
14.3. Forecasting Limitation
14.4. Legal Disclaimer
14.5. Third-Party Data Disclaimer
14.6. Clinical and Regulatory Information Disclaimer
14.7. Company and Product Information Disclaimer

What this section provides: This section clarifies the report’s scope limitations, data-use conditions, forecasting assumptions, legal boundaries, and limitations associated with clinical, regulatory, company, and product information.

List of Tables

TABLE 1: List of Data Sources
TABLE 2: U.S. Home-Based Neurology Devices Market: Market Definition and Scope
TABLE 3: U.S. Home-Based Neurology Devices Market: Research Methodology Framework
TABLE 4: U.S. Home-Based Neurology Devices Market: Key Assumptions
TABLE 5: U.S. Home-Based Neurology Devices Market: Market Ecosystem Overview
TABLE 6: U.S. Home-Based Neurology Devices Market: Stakeholder Analysis
TABLE 7: U.S. Home-Based Neurology Devices Market: Executive Summary Snapshot, 2025
TABLE 8: U.S. Home-Based Neurology Devices Market: Analyst Viewpoint Summary
TABLE 9: U.S. Home-Based Neurology Devices Market: Market Attractiveness Index
TABLE 10: U.S. Home-Based Neurology Devices Market: Historical Market Size, 2021–2024 (US$ Billion)
TABLE 11: U.S. Home-Based Neurology Devices Market: Forecast Market Size, 2026–2035 (US$ Billion)
TABLE 12: U.S. Home-Based Neurology Devices Market: Year-wise Market Size, 2021–2035 (US$ Billion)
TABLE 13: U.S. Home-Based Neurology Devices Market: Drivers; Impact Analysis
TABLE 14: U.S. Home-Based Neurology Devices Market: Restraints; Impact Analysis
TABLE 15: U.S. Home-Based Neurology Devices Market: Opportunities; Impact Analysis
TABLE 16: U.S. Home-Based Neurology Devices Market: Challenges; Impact Analysis
TABLE 17: U.S. Home-Based Neurology Devices Market: Patent & Innovation Analysis, 2021–2025
TABLE 18: U.S. Home-Based Neurology Devices Market: Clinical Workflow Economics Matrix
TABLE 19: U.S. Home-Based Neurology Devices Market: Home Neurology Care Cost-Savings Matrix
TABLE 20: U.S. Home-Based Neurology Devices Market: Health System Procurement Behavior Matrix
TABLE 21: U.S. Home-Based Neurology Devices Market: Patient Adoption and Device Adherence Matrix
TABLE 22: U.S. Home-Based Neurology Devices Market: Neurologist Workflow and Alert-Management Analysis
TABLE 23: U.S. Home-Based Neurology Devices Market: PESTEL Analysis
TABLE 24: U.S. Home-Based Neurology Devices Market: Porter’s Five Forces Analysis
TABLE 25: U.S. Home-Based Neurology Devices Market: Pricing Trend Analysis by Region, 2025–2035
TABLE 26: U.S. Home-Based Neurology Devices Market: Value Chain Analysis
TABLE 27: U.S. Home-Based Neurology Devices Market: Supply Chain Analysis
TABLE 28: U.S. Home-Based Neurology Devices Market: Digitalization and Connected Home Neurology Impact
TABLE 29: U.S. Home-Based Neurology Devices Market: Application & Innovation Landscape
TABLE 30: U.S. Home-Based Neurology Devices Market: FDA Regulatory Framework Analysis
TABLE 31: U.S. Home-Based Neurology Devices Market: FDA Human Factors and Home-Use Device Requirements
TABLE 32: U.S. Home-Based Neurology Devices Market: CMS Reimbursement and Coverage Landscape
TABLE 33: U.S. Home-Based Neurology Devices Market: Remote Physiologic and Therapeutic Monitoring Analysis
TABLE 34: U.S. Home-Based Neurology Devices Market: Commercial Payer Coverage and Prior Authorization Landscape
TABLE 35: U.S. Home-Based Neurology Devices Market: HIPAA, Cybersecurity and Neurological Data Governance
TABLE 36: U.S. Home-Based Neurology Devices Market: Import/Export Restrictions & Tariff Impact
TABLE 37: U.S. Home-Based Neurology Devices Market: Government Initiatives and Neurological Public Health Programs
TABLE 38: U.S. Home-Based Neurology Devices Market: Patient Safety, Reliability and Post-Market Surveillance Framework
TABLE 39: U.S. Home-Based Neurology Devices Market: Product Type Snapshot, 2025
TABLE 40: Segment Dashboard; Definition and Scope, by Product Type
TABLE 41: U.S. Home-Based Neurology Devices Market, by Product Type, 2021–2035 (US$ Billion)
TABLE 42: U.S. Home-Based Neurology Devices Market: Segment Share Analysis, by Product Type, 2025 & 2035 (%)
TABLE 43: U.S. Home-Based Neurology Devices Market: Home EEG and Brain Activity Monitoring Devices Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 44: U.S. Home-Based Neurology Devices Market: Seizure Detection and Patient Safety Devices Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 45: U.S. Home-Based Neurology Devices Market: Movement, Gait and Motor Function Monitoring Devices Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 46: U.S. Home-Based Neurology Devices Market: Home Neurostimulation and Neuromodulation Devices Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 47: U.S. Home-Based Neurology Devices Market: Home Neurorehabilitation and Assistive Devices Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 48: U.S. Home-Based Neurology Devices Market: Application Snapshot, 2025
TABLE 49: Segment Dashboard; Definition and Scope, by Application
TABLE 50: U.S. Home-Based Neurology Devices Market, by Application, 2021–2035 (US$ Billion)
TABLE 51: U.S. Home-Based Neurology Devices Market: Segment Share Analysis, by Application, 2025 & 2035 (%)
TABLE 52: U.S. Home-Based Neurology Devices Market: Epilepsy and Seizure Management Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 53: U.S. Home-Based Neurology Devices Market: Parkinson’s Disease and Movement Disorders Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 54: U.S. Home-Based Neurology Devices Market: Stroke and Post-Stroke Rehabilitation Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 55: U.S. Home-Based Neurology Devices Market: Alzheimer’s Disease, Dementia and Cognitive Monitoring Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 56: U.S. Home-Based Neurology Devices Market: Migraine, Neuropathic Pain and Other Neurological Conditions Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 57: U.S. Home-Based Neurology Devices Market: End User Snapshot, 2025
TABLE 58: Segment Dashboard; Definition and Scope, by End User
TABLE 59: U.S. Home-Based Neurology Devices Market, by End User, 2021–2035 (US$ Billion)
TABLE 60: U.S. Home-Based Neurology Devices Market: Segment Share Analysis, by End User, 2025 & 2035 (%)
TABLE 61: U.S. Home-Based Neurology Devices Market: Patients and Family Caregivers Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 62: U.S. Home-Based Neurology Devices Market: Home Healthcare Agencies and Remote Care Providers Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 63: U.S. Home-Based Neurology Devices Market: Neurology Practices and Specialty Clinics Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 64: U.S. Home-Based Neurology Devices Market: Hospitals and Integrated Health Systems Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 65: U.S. Home-Based Neurology Devices Market: Rehabilitation Providers and Long-Term Care Organizations Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 66: U.S. Home-Based Neurology Devices Market: Technology Type Snapshot, 2025
TABLE 67: Segment Dashboard; Definition and Scope, by Technology Type
TABLE 68: U.S. Home-Based Neurology Devices Market, by Technology Type, 2021–2035 (US$ Billion)
TABLE 69: U.S. Home-Based Neurology Devices Market: Segment Share Analysis, by Technology Type, 2025 & 2035 (%)
TABLE 70: U.S. Home-Based Neurology Devices Market: Wearable and Body-Worn Neurology Devices Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 71: U.S. Home-Based Neurology Devices Market: Portable and Handheld Neurology Devices Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 72: U.S. Home-Based Neurology Devices Market: Noninvasive Neurostimulation Technologies Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 73: U.S. Home-Based Neurology Devices Market: Sensor-Based and Ambient Monitoring Technologies Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 74: U.S. Home-Based Neurology Devices Market: Software-Enabled, AI-Assisted and Cloud-Connected Platforms Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 75: U.S. Home-Based Neurology Devices Market: Procurement Channel Snapshot, 2025
TABLE 76: Segment Dashboard; Definition and Scope, by Procurement Channel
TABLE 77: U.S. Home-Based Neurology Devices Market, by Procurement Channel, 2021–2035 (US$ Billion)
TABLE 78: U.S. Home-Based Neurology Devices Market: Segment Share Analysis, by Procurement Channel, 2025 & 2035 (%)
TABLE 79: U.S. Home-Based Neurology Devices Market: Direct-to-Consumer and Manufacturer E-Commerce Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 80: U.S. Home-Based Neurology Devices Market: Hospital and Health System Home-Care Programs Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 81: U.S. Home-Based Neurology Devices Market: Neurology Practice and Specialty Clinic Prescribing Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 82: U.S. Home-Based Neurology Devices Market: Home Healthcare, DME and Specialty Distributor Channels Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 83: U.S. Home-Based Neurology Devices Market: Retail Pharmacy and Digital Health Marketplace Channels Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 84: U.S. Home-Based Neurology Devices Market: Regional Snapshot, 2025
TABLE 85: Segment Dashboard; Definition and Scope, by Region
TABLE 86: U.S. Home-Based Neurology Devices Market, by Region, 2021–2035 (US$ Billion)
TABLE 87: U.S. Home-Based Neurology Devices Market: Regional Share Analysis, 2025 & 2035 (%)
TABLE 88: West Region U.S. Home-Based Neurology Devices Market: Regional Overview and Trends
TABLE 89: West Region U.S. Home-Based Neurology Devices Market: Key Manufacturers and Procurement Ecosystem
TABLE 90: West Region U.S. Home-Based Neurology Devices Market, by State, 2021–2035 (US$ Billion)
TABLE 91: West Region U.S. Home-Based Neurology Devices Market, by Product Type, 2021–2035 (US$ Billion)
TABLE 92: West Region U.S. Home-Based Neurology Devices Market, by Application, 2021–2035 (US$ Billion)
TABLE 93: West Region U.S. Home-Based Neurology Devices Market, by End User, 2021–2035 (US$ Billion)
TABLE 94: West Region U.S. Home-Based Neurology Devices Market, by Technology Type, 2021–2035 (US$ Billion)
TABLE 95: West Region U.S. Home-Based Neurology Devices Market, by Procurement Channel, 2021–2035 (US$ Billion)
TABLE 96: California Home-Based Neurology Devices Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 97: Washington Home-Based Neurology Devices Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 98: Arizona Home-Based Neurology Devices Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 99: Colorado Home-Based Neurology Devices Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 100: Oregon Home-Based Neurology Devices Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 101: Utah Home-Based Neurology Devices Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 102: Nevada Home-Based Neurology Devices Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 103: New Mexico Home-Based Neurology Devices Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 104: Idaho Home-Based Neurology Devices Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 105: Montana Home-Based Neurology Devices Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 106: Wyoming Home-Based Neurology Devices Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 107: Alaska Home-Based Neurology Devices Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 108: Hawaii Home-Based Neurology Devices Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 109: Northeast Region U.S. Home-Based Neurology Devices Market: Regional Overview and Trends
TABLE 110: Northeast Region U.S. Home-Based Neurology Devices Market: Key Manufacturers and Procurement Ecosystem
TABLE 111: Northeast Region U.S. Home-Based Neurology Devices Market, by State, 2021–2035 (US$ Billion)
TABLE 112: Northeast Region U.S. Home-Based Neurology Devices Market, by Product Type, 2021–2035 (US$ Billion)
TABLE 113: Northeast Region U.S. Home-Based Neurology Devices Market, by Application, 2021–2035 (US$ Billion)
TABLE 114: Northeast Region U.S. Home-Based Neurology Devices Market, by End User, 2021–2035 (US$ Billion)
TABLE 115: Northeast Region U.S. Home-Based Neurology Devices Market, by Technology Type, 2021–2035 (US$ Billion)
TABLE 116: Northeast Region U.S. Home-Based Neurology Devices Market, by Procurement Channel, 2021–2035 (US$ Billion)
TABLE 117: New York Home-Based Neurology Devices Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 118: Massachusetts Home-Based Neurology Devices Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 119: New Jersey Home-Based Neurology Devices Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 120: Pennsylvania Home-Based Neurology Devices Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 121: Connecticut Home-Based Neurology Devices Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 122: Maine Home-Based Neurology Devices Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 123: Vermont Home-Based Neurology Devices Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 124: New Hampshire Home-Based Neurology Devices Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 125: Rhode Island Home-Based Neurology Devices Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 126: Delaware Home-Based Neurology Devices Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 127: South Region U.S. Home-Based Neurology Devices Market: Regional Overview and Trends
TABLE 128: South Region U.S. Home-Based Neurology Devices Market: Key Manufacturers and Procurement Ecosystem
TABLE 129: South Region U.S. Home-Based Neurology Devices Market, by State, 2021–2035 (US$ Billion)
TABLE 130: South Region U.S. Home-Based Neurology Devices Market, by Product Type, 2021–2035 (US$ Billion)
TABLE 131: South Region U.S. Home-Based Neurology Devices Market, by Application, 2021–2035 (US$ Billion)
TABLE 132: South Region U.S. Home-Based Neurology Devices Market, by End User, 2021–2035 (US$ Billion)
TABLE 133: South Region U.S. Home-Based Neurology Devices Market, by Technology Type, 2021–2035 (US$ Billion)
TABLE 134: South Region U.S. Home-Based Neurology Devices Market, by Procurement Channel, 2021–2035 (US$ Billion)
TABLE 135: Texas Home-Based Neurology Devices Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 136: Florida Home-Based Neurology Devices Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 137: Georgia Home-Based Neurology Devices Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 138: North Carolina Home-Based Neurology Devices Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 139: Tennessee Home-Based Neurology Devices Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 140: South Carolina Home-Based Neurology Devices Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 141: Alabama Home-Based Neurology Devices Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 142: Mississippi Home-Based Neurology Devices Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 143: Louisiana Home-Based Neurology Devices Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 144: Arkansas Home-Based Neurology Devices Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 145: Kentucky Home-Based Neurology Devices Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 146: Oklahoma Home-Based Neurology Devices Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 147: Virginia Home-Based Neurology Devices Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 148: Maryland Home-Based Neurology Devices Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 149: West Virginia Home-Based Neurology Devices Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 150: Midwest Region U.S. Home-Based Neurology Devices Market: Regional Overview and Trends
TABLE 151: Midwest Region U.S. Home-Based Neurology Devices Market: Key Manufacturers and Procurement Ecosystem
TABLE 152: Midwest Region U.S. Home-Based Neurology Devices Market, by State, 2021–2035 (US$ Billion)
TABLE 153: Midwest Region U.S. Home-Based Neurology Devices Market, by Product Type, 2021–2035 (US$ Billion)
TABLE 154: Midwest Region U.S. Home-Based Neurology Devices Market, by Application, 2021–2035 (US$ Billion)
TABLE 155: Midwest Region U.S. Home-Based Neurology Devices Market, by End User, 2021–2035 (US$ Billion)
TABLE 156: Midwest Region U.S. Home-Based Neurology Devices Market, by Technology Type, 2021–2035 (US$ Billion)
TABLE 157: Midwest Region U.S. Home-Based Neurology Devices Market, by Procurement Channel, 2021–2035 (US$ Billion)
TABLE 158: Illinois Home-Based Neurology Devices Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 159: Ohio Home-Based Neurology Devices Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 160: Michigan Home-Based Neurology Devices Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 161: Minnesota Home-Based Neurology Devices Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 162: Indiana Home-Based Neurology Devices Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 163: Wisconsin Home-Based Neurology Devices Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 164: Missouri Home-Based Neurology Devices Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 165: Iowa Home-Based Neurology Devices Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 166: Kansas Home-Based Neurology Devices Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 167: Nebraska Home-Based Neurology Devices Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 168: North Dakota Home-Based Neurology Devices Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 169: South Dakota Home-Based Neurology Devices Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 170: U.S. Home-Based Neurology Devices Market: Competitive Landscape Snapshot, 2025
TABLE 171: U.S. Home-Based Neurology Devices Market: Key Company Market Share Analysis, 2025
TABLE 172: U.S. Home-Based Neurology Devices Market: Company Positioning Matrix
TABLE 173: U.S. Home-Based Neurology Devices Market: Product Portfolio Benchmarking of Key Players
TABLE 174: U.S. Home-Based Neurology Devices Market: Strategic Developments, Partnerships, M&A and Product Launches
TABLE 175: Medtronic: Company Profile
TABLE 176: Abbott Laboratories: Company Profile
TABLE 177: Boston Scientific Corporation: Company Profile
TABLE 178: LivaNova: Company Profile
TABLE 179: NeuroPace: Company Profile
TABLE 180: NeuroMetrix: Company Profile
TABLE 181: electroCore: Company Profile
TABLE 182: CEFALY Technology: Company Profile
TABLE 183: Natus Medical Incorporated: Company Profile
TABLE 184: Zeto: Company Profile
TABLE 185: Compumedics: Company Profile
TABLE 186: Empatica: Company Profile
TABLE 187: Smart Monitor Corporation: Company Profile
TABLE 188: Seer Medical: Company Profile
TABLE 189: Rune Labs: Company Profile
TABLE 190: Koneksa Health: Company Profile
TABLE 191: MindMaze: Company Profile
TABLE 192: DIH/Hocoma: Company Profile
TABLE 193: ReWalk Robotics: Company Profile
TABLE 194: Ekso Bionics: Company Profile
TABLE 195: Bioness: Company Profile
TABLE 196: Neofect: Company Profile
TABLE 197: Flint Rehabilitation Devices: Company Profile
TABLE 198: Constant Therapy Health: Company Profile
TABLE 199: Neurolutions: Company Profile
TABLE 200: U.S. Home-Based Neurology Devices Market: Future Market Scenario Analysis, 2026–2035
TABLE 201: U.S. Home-Based Neurology Devices Market: Disruptive Technologies Impact Matrix
TABLE 202: U.S. Home-Based Neurology Devices Market: Emerging Business Trends
TABLE 203: U.S. Home-Based Neurology Devices Market: Business Opportunities for Startups and Existing Players
TABLE 204: U.S. Home-Based Neurology Devices Market: Investment Prioritization Matrix
TABLE 205: U.S. Home-Based Neurology Devices Market: Product Commercialization Readiness Framework
TABLE 206: U.S. Home-Based Neurology Devices Market: Reimbursement Expansion Outlook
TABLE 207: U.S. Home-Based Neurology Devices Market: Long-Term Market Consolidation Outlook
TABLE 208: U.S. Home-Based Neurology Devices Market: Strategic Recommendations for Device Manufacturers
TABLE 209: U.S. Home-Based Neurology Devices Market: Strategic Recommendations for Hospitals and Integrated Health Systems
TABLE 210: U.S. Home-Based Neurology Devices Market: Strategic Recommendations for Neurology Practices and Specialty Clinics
TABLE 211: U.S. Home-Based Neurology Devices Market: Strategic Recommendations for Home Healthcare and Remote Monitoring Providers
TABLE 212: U.S. Home-Based Neurology Devices Market: Strategic Recommendations for Investors and Private Equity Firms
TABLE 213: U.S. Home-Based Neurology Devices Market: Strategic Recommendations for Distributors and Channel Partners
TABLE 214: U.S. Home-Based Neurology Devices Market: Strategic Recommendations for Commercial Payers and Medicare-Focused Organizations
TABLE 215: U.S. Home-Based Neurology Devices Market: Strategic Recommendations for New Entrants and Startups
TABLE 216: U.S. Home-Based Neurology Devices Market: Go-to-Market Strategy Considerations
TABLE 217: U.S. Home-Based Neurology Devices Market: Product Positioning and Portfolio Expansion Guidance
TABLE 218: U.S. Home-Based Neurology Devices Market: Clinical Evidence and Regulatory Strategy
TABLE 219: U.S. Home-Based Neurology Devices Market: Reimbursement and Health Economics Strategy
TABLE 220: U.S. Home-Based Neurology Devices Market: Patient Engagement and Adherence Strategy
TABLE 221: U.S. Home-Based Neurology Devices Market: Partnership, Licensing and Acquisition Opportunities
TABLE 222: U.S. Home-Based Neurology Devices Market: Scope Limitation
TABLE 223: U.S. Home-Based Neurology Devices Market: Data Use Limitation
TABLE 224: U.S. Home-Based Neurology Devices Market: Forecasting Limitation
TABLE 225: U.S. Home-Based Neurology Devices Market: Legal Disclaimer
TABLE 226: U.S. Home-Based Neurology Devices Market: Third-Party Data Disclaimer
TABLE 227: U.S. Home-Based Neurology Devices Market: Clinical and Regulatory Information Disclaimer
TABLE 228: U.S. Home-Based Neurology Devices Market: Company and Product Information Disclaimer

List of Figures

FIGURE 1: U.S. Home-Based Neurology Devices Market Segmentation
FIGURE 2: Market Research Methodology
FIGURE 3: Value Chain Analysis
FIGURE 4: Supply Chain Analysis
FIGURE 5: PESTEL Analysis
FIGURE 6: Porter’s Five Forces Analysis
FIGURE 7: Market Attractiveness Analysis
FIGURE 8: Market Dynamics
FIGURE 9: Innovation & Patent Landscape, 2021–2025
FIGURE 10: Clinical Workflow Economics Framework
FIGURE 11: Home Neurology Care Cost-Savings Framework
FIGURE 12: Health System Procurement Decision Framework
FIGURE 13: Patient Adoption and Device Adherence Framework
FIGURE 14: U.S. Home-Based Neurology Devices Market Size, Historical Trend Analysis, 2021–2024 (US$ Billion)
FIGURE 15: U.S. Home-Based Neurology Devices Market Size, Forecast and Trend Analysis, 2026–2035 (US$ Billion)
FIGURE 16: U.S. Home-Based Neurology Devices Market Year-wise Growth Curve, 2021–2035
FIGURE 17: Product Type Segment Market Share Analysis, 2025 & 2035
FIGURE 18: Product Type Segment Market Size Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 19: Home EEG and Brain Activity Monitoring Devices Market Size Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 20: Seizure Detection and Patient Safety Devices Market Size Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 21: Movement, Gait and Motor Function Monitoring Devices Market Size Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 22: Home Neurostimulation and Neuromodulation Devices Market Size Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 23: Home Neurorehabilitation and Assistive Devices Market Size Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 24: Application Segment Market Share Analysis, 2025 & 2035
FIGURE 25: Application Segment Market Size Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 26: Epilepsy and Seizure Management Market Size Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 27: Parkinson’s Disease and Movement Disorders Market Size Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 28: Stroke and Post-Stroke Rehabilitation Market Size Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 29: Alzheimer’s Disease, Dementia and Cognitive Monitoring Market Size Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 30: Migraine, Neuropathic Pain and Other Neurological Conditions Market Size Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 31: End User Segment Market Share Analysis, 2025 & 2035
FIGURE 32: End User Segment Market Size Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 33: Patients and Family Caregivers Market Size Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 34: Home Healthcare Agencies and Remote Care Providers Market Size Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 35: Neurology Practices and Specialty Clinics Market Size Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 36: Hospitals and Integrated Health Systems Market Size Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 37: Rehabilitation Providers and Long-Term Care Organizations Market Size Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 38: Technology Type Segment Market Share Analysis, 2025 & 2035
FIGURE 39: Technology Type Segment Market Size Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 40: Wearable and Body-Worn Neurology Devices Market Size Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 41: Portable and Handheld Neurology Devices Market Size Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 42: Noninvasive Neurostimulation Technologies Market Size Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 43: Sensor-Based and Ambient Monitoring Technologies Market Size Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 44: Software-Enabled, AI-Assisted and Cloud-Connected Platforms Market Size Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 45: Procurement Channel Segment Market Share Analysis, 2025 & 2035
FIGURE 46: Procurement Channel Segment Market Size Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 47: Direct-to-Consumer and Manufacturer E-Commerce Market Size Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 48: Hospital and Health System Home-Care Programs Market Size Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 49: Neurology Practice and Specialty Clinic Prescribing Market Size Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 50: Home Healthcare, DME and Specialty Distributor Channels Market Size Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 51: Retail Pharmacy and Digital Health Marketplace Channels Market Size Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 52: Regional Segment Market Share Analysis, 2025 & 2035
FIGURE 53: Regional Segment Market Size Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 54: West Region U.S. Home-Based Neurology Devices Market Share and Leading Players, 2025
FIGURE 55: West Region Market Share Analysis by State, 2025
FIGURE 56: West Region Market Size Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 57: California Home-Based Neurology Devices Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 58: Washington Home-Based Neurology Devices Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 59: Arizona Home-Based Neurology Devices Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 60: Colorado Home-Based Neurology Devices Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 61: Oregon Home-Based Neurology Devices Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 62: Utah Home-Based Neurology Devices Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 63: Nevada Home-Based Neurology Devices Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 64: New Mexico Home-Based Neurology Devices Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 65: Idaho Home-Based Neurology Devices Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 66: Montana Home-Based Neurology Devices Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 67: Wyoming Home-Based Neurology Devices Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 68: Alaska Home-Based Neurology Devices Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 69: Hawaii Home-Based Neurology Devices Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 70: Northeast Region U.S. Home-Based Neurology Devices Market Share and Leading Players, 2025
FIGURE 71: Northeast Region Market Share Analysis by State, 2025
FIGURE 72: Northeast Region Market Size Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 73: New York Home-Based Neurology Devices Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 74: Massachusetts Home-Based Neurology Devices Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 75: New Jersey Home-Based Neurology Devices Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 76: Pennsylvania Home-Based Neurology Devices Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 77: Connecticut Home-Based Neurology Devices Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 78: Maine Home-Based Neurology Devices Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 79: Vermont Home-Based Neurology Devices Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 80: New Hampshire Home-Based Neurology Devices Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 81: Rhode Island Home-Based Neurology Devices Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 82: Delaware Home-Based Neurology Devices Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 83: South Region U.S. Home-Based Neurology Devices Market Share and Leading Players, 2025
FIGURE 84: South Region Market Share Analysis by State, 2025
FIGURE 85: South Region Market Size Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 86: Texas Home-Based Neurology Devices Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 87: Florida Home-Based Neurology Devices Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 88: Georgia Home-Based Neurology Devices Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 89: North Carolina Home-Based Neurology Devices Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 90: Tennessee Home-Based Neurology Devices Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 91: South Carolina Home-Based Neurology Devices Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 92: Alabama Home-Based Neurology Devices Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 93: Mississippi Home-Based Neurology Devices Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 94: Louisiana Home-Based Neurology Devices Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 95: Arkansas Home-Based Neurology Devices Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 96: Kentucky Home-Based Neurology Devices Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 97: Oklahoma Home-Based Neurology Devices Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 98: Virginia Home-Based Neurology Devices Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 99: Maryland Home-Based Neurology Devices Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 100: West Virginia Home-Based Neurology Devices Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 101: Midwest Region U.S. Home-Based Neurology Devices Market Share and Leading Players, 2025
FIGURE 102: Midwest Region Market Share Analysis by State, 2025
FIGURE 103: Midwest Region Market Size Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 104: Illinois Home-Based Neurology Devices Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 105: Ohio Home-Based Neurology Devices Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 106: Michigan Home-Based Neurology Devices Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 107: Minnesota Home-Based Neurology Devices Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 108: Indiana Home-Based Neurology Devices Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 109: Wisconsin Home-Based Neurology Devices Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 110: Missouri Home-Based Neurology Devices Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 111: Iowa Home-Based Neurology Devices Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 112: Kansas Home-Based Neurology Devices Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 113: Nebraska Home-Based Neurology Devices Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 114: North Dakota Home-Based Neurology Devices Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 115: South Dakota Home-Based Neurology Devices Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 116: Competitive Landscape; Key Company Market Share Analysis, 2025
FIGURE 117: Company Positioning Matrix
FIGURE 118: Key Player Product Portfolio Benchmarking
FIGURE 119: Strategic Developments, Partnerships, M&A and Product Launches
FIGURE 120: Home-Based Neurology Device Innovation Roadmap
FIGURE 121: Regulatory, Reimbursement and Commercialization Benchmarking
FIGURE 122: At-Home EEG and Continuous Brain Monitoring Adoption Roadmap
FIGURE 123: AI-Assisted Neurological Digital Biomarker Opportunity Map
FIGURE 124: Predictive Seizure and Fall Detection Growth Roadmap
FIGURE 125: Home Neurorehabilitation Technology Opportunity Map
FIGURE 126: Noninvasive Neuromodulation Adoption Roadmap
FIGURE 127: Future Market Scenario Analysis, 2026–2035
FIGURE 128: Disruptive Technologies Impact Matrix
FIGURE 129: Emerging Business Trends Matrix
FIGURE 130: Investment Prioritization Matrix
FIGURE 131: Strategic Growth Roadmap for U.S. Home-Based Neurology Device Companies
FIGURE 132: Go-to-Market Strategy Framework
FIGURE 133: Product Positioning and Portfolio Expansion Framework
FIGURE 134: Clinical Evidence, Reimbursement and Patient Engagement Framework
FIGURE 135: Report Scope and Disclaimer Framework